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ABSTRACT 
 
A NOVEL CCR5 MUTATION IN SOOTY MANGABEYS REVEALS SIVSMM 
INFECTION OF CCR5-NULL NATURAL HOSTS: EXAMINING THE POTENTIAL 
ROLES OF ALTERNATIVE ENTRY PATHWAYS IN HIV AND SIV INFECTION 
 
Nadeene E. Riddick 
 
Ronald G. Collman, M.D. 
 
Natural hosts of SIV, such as sooty mangabeys (SM), maintain high levels of virus 
replication, but do not typically develop CD4+ T cell loss and immunodeficiency.  
Understanding the virus/host relationship in natural hosts will enable better understanding 
of pathogenic HIV infection of humans.  Host cell targeting in vivo is an important 
determinant of pathogenesis, and is defined mainly by expression of coreceptors used by 
the virus for entry, in conjunction with CD4.  Established dogma holds that, with rare 
exceptions, SIV uses CCR5 for entry.  However, SM and other natural hosts express 
extremely low CCR5 levels on CD4+ T cells.  I identified a novel SM-CCR5 mutant 
allele containing a two base-pair deletion (CCR5∆2) that results in a non-functional 
protein.  Using PCR screening and direct sequence confirmation in a large captive SM 
colony, I found an allelic frequency of 26% for CCR5∆2, along with 3% for a previously-
described CCR5∆24 null allele.  Notably, SM-CCR5∆2 was also present in West African 
wild-living SM.  Approximately 8% of captive SM were homozygous for CCR5-null 
alleles.  Surprisingly, SIVsmm infection was not significantly less prevalent in SM 
lacking functional CCR5 compared to CCR5-expressing animals, and CCR5-null animals 
displayed high-level viremia.  Primary PBMC from SM were permissive for SIVsmm 
replication in both the absence and presence of CCR5 in vitro.  Pseudotype virions 
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carrying Envs from both CCR5-null and wild-type infected SM used CXCR6 and GPR15 
efficiently for entry in transfected cells, suggesting likely alternative entry molecules.  In 
preliminary studies using human cells, I found that CD4+ T cell expression of CXCR6 
and GPR15 was predominantly on central and effector memory subsets, although 
expression patterns on SM cells will require antibodies that can detect SM proteins.  This 
finding challenges the long-standing notion that CCR5 is the exclusive coreceptor used 
for SIV entry in vivo, and reveals that SIVsmm can infect target cells in vivo using non-
CCR5 entry pathways.  Since CD4/coreceptor interactions determine viral tropism and 
cell targeting, these results suggest that infection in natural host SM may involve target 
cells defined by the distribution and use of alternative coreceptors CXCR6 and GPR15.  
Combined with restricted expression of CCR5 on critical target cells previously 
described, alternative coreceptor-dependent targeting may allow virus replication in more 
expendable cells without loss of immune cell homeostasis.  We hypothesize that SM 
natural hosts may have evolved to restrict expression of CXCR6 and GPR15, in addition 
to CCR5, to dispensable cell subsets, thus allowing for high viral replication without 
causing disease.  Future studies comparing CXCR6 and GPR15 expression profiles in 
natural and non-natural hosts will be of importance in determining the role of alternative 
coreceptors in natural hosts in vivo.  
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GENERAL INTRODUCTION 
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Epidemiology 
 
In 1983, two laboratories identified human immunodeficiency virus (HIV) as the 
virus that causes acquired immunodeficiency syndrome (AIDS) (7, 82).  Over the past 30 
years, HIV has become a leading cause of death worldwide especially in regions of sub-
Saharan Africa (1).  As of 2010, an estimated 34 million people are living with HIV 
worldwide, which has increased 17% from the number of infected individuals in 2001.  
This increase in HIV prevalence reflects new infections as well as an increase in the life 
expectancy of HIV-infected individuals due to more effective therapeutics and a 
significant rise in access to antiretroviral therapy (ART).  Although there is an increase in 
the total number of people living with HIV over the past decade, the estimated number of 
new HIV cases (2.7 million) was 21% lower in 2010 than the number of new infections 
in 1997, at the peak of the HIV epidemic (1).  However, there is still no cure or vaccine 
available against HIV, which is a major issue since a large proportion of people living 
with or at risk for infection, in developing countries, still do not have access to treatment 
or care. 
HIV is transmitted through the transfer of bodily fluids (i.e. blood, semen, vaginal 
fluid, and breast milk) from an infected individual to an uninfected recipient.  The major 
routes of HIV transmission are unprotected sex, contaminated needles, during birth 
(perinatal), and through breast milk (25, 47, 92) Notably, the main route of transmission 
differs from region to region.  Historically, in the U.S., HIV infection predominantly 
affected intravenous drug users and men who have sex with men (MSM).  Although, 
these groups remain at high risk for infection, heterosexual transmission accounts for a 
growing number of HIV cases in the U.S., especially among women.  The HIV epidemic 
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in Eastern Europe is primarily driven by intravenous drug users, while the HIV epidemic 
in Sub-Saharan Africa and parts of the Caribbean are mainly the result of heterosexual 
contact.  
 
HIV disease pathogenesis 
 
HIV infects CD4+ T lymphocytes and macrophages, which play critical roles in 
both the innate and adaptive arms of the immune system.  A typical HIV infection 
consists of three stages: the acute (primary) infection, the chronic infection (clinical 
latency), and the onset of AIDS.  The acute phase generally lasts several weeks with 
symptoms ranging from asymptomatic to flu-like in infected individuals.  During this 
stage, an inverse correlation between plasma viremia and peripheral blood CD4+ T cell 
counts is observed, in which CD4+ T cell counts decrease concomitant with peak viremia 
(24).  Early in infection, memory CD4+ T lymphocytes are preferential targets of HIV, 
likely due to their moderate to high CCR5 expression and activated state.  The majority 
of activated memory CD4+ T cells reside in the gut associated lymphoid tissue (GALT).  
HIV infection leads to a rapid and massive depletion of these cells, which is sustained 
throughout the course of infection (13, 89).  Towards the end of the acute phase, viral 
loads decline to a set level and peripheral blood CD4+ T cell counts partially rebound as 
demonstrated in Figure 1-1.   
The chronic phase of infection is characterized by a prolonged asymptomatic 
period lasting for many years.  Throughout this period of clinical latency, viral loads 
gradually increase while CD4+ T cell counts slowly decline (35).  Notably, infected 
persons remain infectious during this period (59, 80).  At the end stage of disease (AIDS), 
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CD4+ T cell counts in the blood are extremely low likely due to direct viral killing of 
infected cells, an increased rate of apoptosis of infected and bystander (uninfected) cells, 
and cell-mediated killing of infected cells (96).  When CD4+ T cell counts decrease 
below a critical threshold, cell-mediated immunity is severely compromised and the host 
becomes more susceptible to opportunistic infections (72, 83).  
The development and use of antiretroviral therapy (ART) has dramatically 
reduced HIV-related mortality and morbidity in middle to high-income countries where 
access to ART is available.  In the late 1980’s, antiretroviral (ARV) drugs became 
available for use by HIV-infected patients.  However treatment with a single ARV drug 
led to drug resistant strains of the virus given that HIV mutates at a high rate due to its 
rapid and persistent replication combined with the lack of polymerase proofreading 
activity (50, 51).  In the mid 1990’s, combination therapy was developed, which defends 
against HIV resistance by suppressing HIV replication at multiple stages in the virus life 
cycle.  Highly active antiretroviral therapy (HAART) consists of a combination of three 
or more antiretroviral drugs that maximally suppress HIV replication.  With proper use, 
HAART suppresses HIV viral loads below detectable levels reducing the likelihood of 
HIV transmission by infected individuals.  However, inconsistent use of HAART can 
lead to multi-drug resistant strains, which considerably limits future treatment options. 
Unfortunately, access to drug treatments are not uniformly available in low and middle-
income countries, where treatment needs are the greatest. 
While the majority of HIV-infected persons ultimately progress to AIDS if left 
untreated, a small percentage of HIV-infected individuals appear to naturally control the 
infection, called long term non-progressors (LTNP).   There is no universally accepted 
 5 
definition for LTNP, but in general these infected individuals maintain a normal range of 
CD4 T cell counts in the peripheral blood without the use of antiretroviral therapy, and do 
not progress to AIDS after prolonged periods of observation.   LTNP may have 
detectable viral loads that typically do not exceed more than 2,000 copies/ml.  A subset 
of LTNP called elite controllers (EC) have undetectable viral loads (< 50 copies/ml) and 
naturally maintain normal CD4 T cell counts in the blood, without the use of 
antiretroviral therapy (28).  
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Figure 1-1.  Viral and cellular parameters of disease progression during HIV-1 infection.  
Acute infection is characterized by a peak in viral load and a rapid increase in immune activation.  
During this phase, mucosal CD4 T cells are severely depleted while a transient decrease in 
peripheral blood (PB) CD4 T cells is observed, which partially rebounds towards the early stage 
of chronic infection.  During chronic infection, viral loads are maintained at a viral set point and 
immune activation remains elevated while mucosal CD4 T cell counts remain low and CD4 T 
cells in the periphery begin to steadily decline.  When PB CD4 T cells decrease below a critical 
threshold, this defines the onset of AIDS, which is characterized by an increase in viral 
replication and severe immunodeficiency, resulting in opportunistic infections.  Schematic was 
adapted from Grossman, Z. et al. Nature Medicine 2006. 
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SIV: origins of HIV-1 and HIV-2	  
 
Through comparative sequence analysis, the origins of HIV have been traced to 
specific strains of SIV found in African non-human primates (NHP).   HIV-1 is the result 
of cross-species transmission of a strain of simian immunodeficiency virus (SIV) found 
in chimpanzees, SIVcpz (56, 58, 101).  Hahn et al. determined that all examined HIV-1 
isolates from groups M, N and O were only closely related to lineages of SIVcpz found in 
the chimpanzee subspecies, Pan troglodyte troglodyte, inferring that on at least three 
separate occasions, SIVcpz crossed into the human population (40).  Chimpanzees were 
originally categorized as a natural host of SIV, however recent studies revealed that SIV-
infected chimpanzees exhibited increased mortality and morbidity compared to 
uninfected animals, and they are now designated as intermediate hosts of SIV (60).  
Studies indicate that SIVcpz contains a recombinant genome with regions similar to two 
strains of SIV, SIVrcm found in red-capped mangabeys (RCM; Cercocebus torquatus) 
and SIVgsn found in greater-spot nosed monkey (Cercopithecus nictitans) (5).  HIV-2 
and SIVmac are also the result of two separate cross-species transmission events of 
SIVsmm, a strain of SIV found in sooty mangabeys (SM), into the human and rhesus 
macaques (RM) populations, respectively (19, 20, 41, 42, 52).  Currently, over 40 
different species-specific SIV strains have been identified in African NHP, thus the 
possibility of another zoonosis into the human population is plausible.  The phylogenetic 
relationship between SIVcpz/HIV-1 and SIVsmm/HIV-2 is depicted in Figure 1-2. 
SIV is endemic in African NHP and infected natural hosts live a normal lifespan 
and remain asymptomatic, despite high viral loads (95).  In stark contrast, SIV-infected 
non-natural hosts (i.e. Asian macaques) experience an AIDS-like disease that results in 
 8 
death due to opportunistic infections.  The pathogenic potential of SIV was first observed 
when lymphoma outbreaks occurred in captive Asian macaques (RM and stump-tailed 
macaques), which had been in contact with SIV-infected SM prior to the outbreaks.  
Inadvertently, this virus was serially transmitted to other macaques giving rise to the 
well-established SIVmac strain (27).  SIV-infected RM exhibit a disease course similar to 
that of HIV-infected humans, therefore SIV-infected RM serve as a valuable animal 
model to study HIV infection. 
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Figure 1-2.  Phylogenetic relationship among HIV and SIV strains.  This phylogenetic tree 
was generated based on the similarity of pol gene sequences between various strains of HIV and 
SIV.  This tree clearly demonstrates that HIV-1 (groups M, N and O) is closely related to SIVcpz 
pol sequences while HIV-2 is most closely related to SIVsmm.   Notably, HIV-1 N group and 
SIVagmSAB have recombined genomes.  Based on pol gene relatedness, the HIV-1 N group is 
more closely related to the HIV-1 M group, as shown.  However, based on env gene phylogenies, 
the HIV-1 N group clusters within the SIVcpz (P.t.t) clade.  SIVagmSAB is recombinant with other 
SIVagm strains and SIVsmm.  Due to a recombination event in the pol gene of SIVagmSAB, this 
branch is placed between SIVagm and SIVsmm, however the placement of SIVagmSAB branch 
does not reflect true evolutionary history.  Small arrows indicate the branch position of 
recombinant viruses (HIV-1 N group and SIVagmSAB) based on an env phylogenetic tree 
reconstruction.  Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 
1999. 
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Chronic Immune Activation 
 
Chronic immune activation is a key feature that distinguishes non-pathogenic 
from pathogenic infection.  Typical features of HIV-associated chronic immune 
activation include a higher frequency of activated T and B cells, increased lymphocyte 
turnover, high activation-induced cell death and high levels of pro-inflammatory 
cytokines and chemokines in serum from infected individuals.  Interestingly, the acute 
phase of SIV infection in natural and non-natural hosts is characterized by strong innate 
and adaptive immune responses to the virus.  However, natural hosts downregulate this 
response early in the chronic phase and maintain a low immune activation state 
throughout infection.  
Both viral and host factors appear to contribute to chronic immune activation.  
The role of virus-induced immune activation is demonstrated by the fact that ART 
reduces immune activation in HIV-infected persons (32).  However, viral factors alone 
cannot account for HIV/SIV-associated immune activation since SIV-infected natural 
hosts exhibit high levels of viral loads while immune activation during the chronic phase 
of infection is relatively low (15, 96).  Viral factors associated with immune activation 
likely include HIV/SIV-induced innate and adaptive immune responses and re-activation 
of latent viruses, while host factors associated with immune activation may include 
mucosal immune dysfunction and homeostatic proliferation.   
Numerous HIV/SIV-specific viral factors may contribute to chronic immune 
activation including: (i) gp120-mediated signaling through CD4 and/or coreceptor, (ii) 
specific antiviral adaptive immune responses elicited by HIV/SIV-specific T and B cells 
(68), and (iii) stimulation of the innate immune response via pattern recognition receptors 
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(toll-like receptors) that recognize components of bacterial pathogens (which may have 
entered the bloodstream as a result of microbial translocation) and HIV-derived ligands 
(HIV single-stranded RNA) (4, 12).  Additionally, during the late stage of disease, 
reactivation of latent viruses may contribute to chronic immune activation.  This can 
occur in the setting of a compromised immune system where latent herpes viruses (i.e. 
cytomegalovirus [CMV] and Epstein-Barr virus [EBV]) frequently reactivate, which may 
stimulate large numbers of T cells specific for CMV and/or EBV viral antigen (73). 
During early stages of infection, studies suggest that damage to the 
gastrointestinal (GI) immune system may increase systemic immune activation during the 
chronic phase of pathogenic HIV/SIV infection.  During acute infection, mucosal CD4 T 
cells are severely depleted, likely since a large proportion of these cells express the HIV 
co-receptor, CCR5 (45, 79).  Mucosal CD4 T cells are primarily comprised of Th1 and 
Th17 cells, which produce and secrete interferon-gamma (IFN-g) and interleukin-17 (IL-
17), respectively.  Profound depletion of Th17 cells is associated with a breakdown in the 
mucosal barrier resulting in translocation of microbial products (i.e. LPS and flagellin) 
from the intestinal lumen to systemic circulation (12, 33).  Aberrant circulation of 
microbial products may cause broad immune activation through TLR-mediated 
stimulation of immune cells as well as triggering bystander activation of circulating 
lymphocytes.  Evidence demonstrating a causal relationship between microbial 
translocation and immune activation is seen in SIV-infected natural hosts where lack of 
microbial translocation in these animals is associated with attenuated chronic immune 
activation (6, 12, 16, 97).   
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 Another factor that potentially affects chronic immune activation is homeostatic 
proliferation.  Homeostatic proliferation is the ability of T cells to divide in the absence 
of activation, and is aimed at repopulating particular T cell pools.  During acute HIV 
infection, there is severe and persistent depletion of mucosal CD4 T cells in the gut as 
well as transient depletion of CD4 T cells in the blood.  The adaptive immune system 
responds by proliferation of HIV/SIV-specific T cells in response to encountering viral 
antigen, however antigen-independent homeostatic proliferation also occurs in an attempt 
to replenish the continuously depleting CD4 T cell pool.  A clear relationship between 
intestinal CD4 T cell depletion and systemic/intestinal CD4 T cell proliferation was 
demonstrated in HIV-infected and uninfected individuals (44, 98). 
 
Divergent host responses to SIV infection 
 
  As previously mentioned, SIV infection of natural hosts is non-pathogenic while 
HIV/SIV infection of non-natural hosts results in a pathogenic infection, characterized by 
chronic immune activation, immunodeficiency and ultimately death as a result of 
opportunistic infections.  However, the mechanisms underlying the absence of disease in 
infected natural hosts are poorly understood.  Schematics highlighting similarities and 
differences in key parameters of pathogenic and non-pathogenic SIV/HIV infections are 
depicted in Figure 1-3. 
There are a number of key features that differ between SIV-infected natural and 
non-natural hosts, however one shared feature is high levels of virus replication.  
Originally, researchers hypothesized that absence of disease in infected natural hosts may 
be due to non-pathogenic or less fit virus.  However, subsequent studies indicated that 
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lack of disease progression in natural hosts is not associated with low levels of viral 
replication (15, 53, 84, 96).  Many studies have confirmed that infected natural hosts 
exhibit viral loads equal to or greater than viral loads seen in SIV-infected non-natural 
hosts (15, 84, 94).   
While both non-pathogenic and pathogenic infections result in high viral loads, 
pathogenic infections result in CD4+ T cell loss in the blood, and progression to AIDS, 
which is extremely rare in infected natural hosts (14, 76).  However, studies have 
demonstrated rare instances in which SIV-infected SM experienced severe depletion of 
peripheral blood CD4+ T cells, either naturally or experimentally, yet these animals did 
not progress to AIDS (69, 70).  This observation suggests that natural hosts have 
developed at least two levels of protection in response to SIV infection: i) protection from 
loss of CD4+ T cells during SIV infection (possibly due to mechanisms which maintain 
homeostasis of the immune system), and ii) protection from AIDS when CD4+ T cells 
are lost (69, 70).  
As previously mentioned, a key feature that differs between infected natural and 
non-natural hosts is chronic immune activation.  Immune activation during the acute 
phase of infection is exhibited in both pathogenic and non-pathogenic infections, 
however studies indicate that infected natural hosts downregulate immune responses 
through mechanisms not fully understood, during early chronic infection (10, 48, 57).  
Differential downregulation of innate immune responses can be observed in SM and 
African green monkeys (AGM) natural hosts, which downmodulate type I interferon 
responses within four to six weeks post-infection, whereas SIV-infected RM exhibit 
persistently high interferon responses throughout the chronic phase of infection (48).  
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This is only one such example where natural hosts have evolved mechanisms to attenuate 
chronic immune activation. 
Intriguingly, depletion of gut memory CD4+ T cells occurs in both SIV-infected 
natural and non-natural hosts (45, 79), however microbial translocation is only observed 
in pathogenic SIV infections.  Microbial translocation, which likely results from a breach 
in the gut epithelial barrier, is thought to be a major driver of chronic immune activation 
(12, 33).  Studies suggest that the sparing of CD4+ Th17 cells in the gut of infected 
natural hosts may contribute to intact gut immunity and the absence of microbial 
translocation in these hosts (11).  Notably, an association between circulating microbial 
products and immune activation was emphasized in a study where a single dose of LPS 
was administered to chronically SIVagm-infected AGM, which led to an increase in 
proliferation and activation of CD4+ T cells, as well as an increase in viral loads (78).  
However, whether induced-immune activation in these animals would have progressed to 
disease is unknown since this was a short-term study. 
Another major difference between natural and non-natural hosts is the level of 
CCR5 expression on CD4+ T cells.  SIV natural hosts express extremely low levels of 
CCR5 on CD4+ T cells from the blood, lymph nodes and mucosal tissues compared to 
CCR5 levels on CD4+ T cells of non-natural hosts (77).  Interestingly, both natural and 
non-natural hosts exhibit similar levels of CCR5 expression on CD8+ T cells, which calls 
to question if low levels of CCR5 expression on natural host CD4+ T cells is an 
evolutionary adaptation in response to SIV.  Furthermore, several natural host species 
(i.e. SM, AGM, mandrills, and sun-tailed monkeys) exhibit extremely low CCR5 
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expression levels on CD4+ T cells demonstrating convergent evolution of the natural host 
immune system in response to endemic lentiviruses.   
It has been speculated that low CCR5 levels on CD4+ T cells may be beneficial to 
the host for a number of reasons, such as: (i) a reduction in target cells for virus 
replication, and (ii) decreased homing of activated CD4+ T cells to sites of inflammation.  
The latter point suggests that low CCR5 levels may also contribute to the low chronic 
immune activation state seen in infected natural hosts, since fewer potential target cells 
are recruited to sites of inflammation, which are likely sites of active virus replication.  
Additionally, low CCR5 levels on CD4+ T cells has been hypothesized to contribute to 
non-pathogenicity in natural hosts (75), creating a paradox since infected natural hosts 
exhibit robust viral replication.  My work addresses in part, mechanisms by which high 
viral loads can be sustained in the face of restricted CCR5 expression on natural host 
target cells. 
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Figure 1-3.  Comparison of disease course in HIV/SIV-infected natural and non-natural 
hosts.  A) Viral and cellular parameters of HIV/SIV infection in non-natural hosts were described 
in detail in Fig. 1-1.  B) In SIV-infected natural hosts, viral loads peak during acute infection then 
decrease to a viral “set point” that persists throughout the lifetime of the infected animal.  
Peripheral blood CD4+ lymphocytes transiently decrease during the acute infection then rebound 
and are maintained throughout the infection while CD4 T cells in the MALT are severely 
depleted and do not rebound to pre-infection levels.  Additionally, generalized immune activation 
in SIV-infected natural hosts increases during acute infection but is downregulated during the 
chronic phase of infection.  Paiardini, M. et al. Ann. Rev. Med. 2009. 
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HIV/SIV life cycle  
 
HIV/SIV are members of the Lentivirus genus within the Retroviridae family. 
Lentiviruses contain a positive-sense, single-stranded RNA genome that is enveloped in a 
lipid bilayer derived from the host cell.  HIV/SIV particles contain two copies of their 
RNA genome enclosed in a capsid core, which is surrounded by a lipid bilayer, studded 
with the viral envelope glycoprotein (Env) (43).  HIV and SIV genomes are comprised of 
nine genes.  The structural genes (gag, pol and env) encode proteins required for the 
production and assembly of new virion particles, while the accessory genes (tat, rev, nef, 
vif, vpr, and vpu [SIVcpz/HIV-1] or vpx [many SIVs/HIV-2]) have regulatory functions, 
which affect the synthesis and processing of viral RNA as well as viral infectivity.  Long 
terminal repeats (LTR) flank the viral genome and play an integral role in the insertion of 
the viral genome into the host DNA.   
HIV/SIV utilizes CD4 and a co-receptor (chemokine or chemokine-like receptor) 
for entry into target cells (21, 26, 29, 36, 62, 86).  Steps involved in virus entry will be 
discussed in detail in the following section.  Once inside the cell, HIV/SIV usurp cellular 
machinery for viral propagation, requiring only three additional enzymes, reverse 
transcriptase (RT), protease and integrase, which are packaged in the virion capsid and 
deposited into target cells upon viral entry.  Reverse transcriptase is a RNA-dependent 
DNA polymerase, which is extremely error-prone since it lacks proof-reading activity.  
RT reverse transcribes the viral RNA genome into a complementary DNA copy, and then 
degrades the RNA strand of the RNA/DNA hybrid with its RNase H activity.  Cellular 
polymerases synthesize the complementary strand resulting in a double stranded DNA 
copy of the viral genome.  Next, viral DNA is transported to the nucleus where viral 
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integrase process the LTRs and catalyze the insertion of the proviral DNA into the host 
genome.  One characteristic that distinguishes lentiviruses from other retroviruses is their 
ability to replicate in non-dividing cells.  Integrated proviral DNA is transcribed and 
translated generating structural polyproteins, which are processed and used to assemble 
new virion particles, as well as copies of full-length viral genomes that are incorporated 
into new virions (46).  The final steps of the life cycle include budding from the cell 
surface and maturation of virion particles, which requires the cleavage of polyproteins 
into mature matrix protein by viral proteases. 
 
HIV/SIV entry 
 
HIV/SIV entry into target cells is generally believed to occur via a receptor-
mediated, pH-independent pathway (23).  Several chemokine receptors and chemokine 
receptor-like proteins mediate HIV/SIV entry in vitro (31), however CCR5 and CXCR4 
are thought to play a dominant role in HIV entry in vivo, whereas it is generally accepted 
that CCR5 alone mediates SIV entry in vivo (88).  HIV/SIV entry mechanisms are 
extremely similar; therefore only HIV entry will be discussed in detail.   
The viral protein required for target cell entry is the envelope glycoprotein, 
gp160, a 160 kDa polyprotein, which is cleaved by cellular proteases to yield two 
subunits: (i) gp120, the surface subunit and (ii) gp41, the transmembrane subunit (2, 102, 
105).  Gp120 and gp41 are non-covalently linked and functionally exist as a trimer of 
dimers on the viral particle (49, 64, 66, 103, 107, 108).  Each trimer is referred to as an 
envelope spike; on average HIV virions are studded with ten envelope spikes (43).  The 
gp120 subunit is localized on the surface of the viral particle where it can interact with 
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cellular receptors.  This subunit is composed of five constant regions (C1-C5), which 
contain critical domains for binding to entry receptors, as well as five variable regions 
(V1 – V5) (71, 106) that can withstand high sequence variability allowing them to act as 
immunological shields, protecting the conserved, more critical regions, from antibody 
neutralization.  In another effort to evade the humoral immune response, gp120 is heavily 
glycosylated obscuring much of its surface from antibody recognition (65).   
In order for HIV to gain entry into a target cell, the gp120 subunit must first bind 
the cellular receptor, CD4 (26, 62).  This interaction causes conformational changes in 
gp120 resulting in the formation and exposure of the coreceptor binding site (87).  The 
third variable loop (V3) of gp120 is critical for coreceptor binding.  V3 is composed of 
three structural regions: (i) the base, which sits closest to the core, (ii) the flexible stem 
region, and (iii) the highly conserved tip region.  Studies indicate that the base of V3 
interacts with the N-terminus of CCR5, while the tip and stem regions of V3 interact with 
CCR5 extracellular loops (ECL) (54, 55).  Figure 1-4 shows the crystal structure of 
trimeric gp120 bound to the CD4 receptor.  In this model, the V3 loop of each gp120 
monomer is extended towards the cell membrane (55).  Upon coreceptor binding, 
subsequent conformational changes occur in gp41 exposing the hydrophobic fusion 
peptide, which quickly inserts into the target cell membrane (38, 39).  Gp41 contains two 
heptad repeat regions (HR1 and HR2). Once triggered, HR2 domains in each gp41 
subunit fold back on HR1 domains forming a complex (18, 104), the 6-helix bundle, 
which brings the viral and target cell membranes into close proximity promoting fusion 
through mechanisms that are not fully understood (67).  Once fusion occurs, the viral 
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capsid core, containing the viral genome, is released into the target cell.  HIV receptor 
engagement and entry steps are depicted in Figure 1-5.  
 
 
Figure 1-4.  Crystal structure of gp120 trimer with exposed V3 domains conjugated to CD4.  
Trimeric model of gp120 where the core (grey) and V3 loops (red) are superimposed onto the 
structure of a four-domain CD4 molecule (yellow).  In the CD4-triggered state, the V3 domains 
protrude 30 angstrom away from the viral envelope and towards the cellular membrane.  Image 
obtained from Kwong, P. et al. Science 2005. 
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Figure 1-5.  Model of HIV/SIV entry.  A trimeric HIV/SIV Env is shown attached to the viral 
membrane.  Once the virus comes into close proximity with the cellular membrane, the surface 
unit of Env (gp120) binds to the cellular receptor, CD4.  Upon binding, conformational changes 
occur in Env allowing gp120 to bind to the coreceptor.  Gp120/coreceptor engagement causes 
subsequent conformational changes exposing the fusion peptide of gp41, which inserts into the 
cellular membrane.  Formation of the 6-helix bundle brings the viral and cellular membranes into 
close proximity, which promotes membrane fusion, ultimately resulting in viral entry.  Adapted 
from Moore, J.P., Doms, R.W. PNAS 2003. 
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HIV/SIV entry coreceptors and tropism 
 
Chemokine receptors are critical for HIV/SIV entry into target cells.  These 
receptors are members of a large protein family of G protein-coupled receptors (GPCR).  
Physiologically, chemokine receptors interact with their cognate ligand, which activates 
signaling pathways, ultimately resulting in cell migration.  Chemokine receptors are 
composed of seven transmembrane helices, which form three extracellular loops, three 
intracellular loops, an N-terminus exposed to the extracellular space, and a C-terminus 
exposed to the cytosol.  Chemokine receptors contain a conserved DRYLAVHA 
sequence (“DRY motif”) in the second intracellular loop that has been implicated in G-
protein interaction and signaling.  In addition to the role chemokine receptors play in 
cellular immunity, these receptors have been extensively studied over the past decade due 
to their integral role in HIV/SIV entry.  
Various in vitro studies indicate that two particular regions of CCR5 and CXCR4 
are critical for HIV entry, the N-terminal domain and extracellular loop two (ECL2).   
Studies suggest that tyrosine resides in the N-terminal domain of CCR5 are post-
translationally sulfated; these modifications are critical for high affinity interactions 
between the coreceptor and CD4-triggered HIV-1 envelopes (22, 34, 93).  As previously 
mentioned, the V3 loop plays a central role in coreceptor binding and tropism.  Based on 
NMR and crystallographic data, Kwong et al. demonstrated that regions of the V3 base 
interacted with sulfated tyrosines located in the N-terminus of CCR5 (54).  Additionally, 
the use of chimeric receptors and site-directed mutagenesis of ECLs revealed that ECL2 
also plays a critical role in viral entry (9, 17, 30, 81, 86).  Taken together, these studies, 
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as well as others, implicate the importance of CCR5 N-terminus and ECL2 in HIV-1 
gp120 binding and entry. 
Receptor expression is a principal determinant of viral tropism.  Early 
characterization of HIV entry revealed two viral phenotypes: (i) syncytia-inducing or T 
cell-tropic viral isolates that infected primary lymphocytes and lymphocyte cell lines, but 
not primary macrophages, and (ii) non-syncytia-inducing or M-tropic viral isolates, 
which infected primary macrophages and primary lymphocytes, but not transformed T 
cell lines (3, 90, 91, 99).  Subsequent studies revealed that differences in target cell 
tropism by M-tropic and T-tropic viral isolates was attributed in large part to the cellular 
expression of CCR5 and CXCR4 on macrophage and T cell lines, respectively.  This 
observation lead to the current classification system where HIV viruses are categorized 
based on entry coreceptor use: (i) R5 viruses use CCR5 for entry, (ii) X4 viruses use 
CXCR4, and (iii) R5X4 or dual-tropic viruses use both CCR5 and CXCR4 (8).  
Studies indicate that R5-tropic viruses are commonly transmitted during HIV 
infection.  These viruses predominate during early infection and exist throughout all 
stages of disease.  Interestingly, in 50% of HIV infections, R5-tropic viruses acquire the 
ability to use CXCR4.  Acquisition of CXCR4 use shifts viral tropism from 
predominantly CCR5-expressing memory CD4+ T cells to CXCR4-expressing naïve 
CD4+ T cells (74, 100), which has been associated with accelerated disease progression 
(63). 
In contrast to HIV, SIV strains use CCR5 but not CXCR4.  However, a number of 
additional molecules function in vitro for SIV entry.  Based largely on studies using 
human molecules, these include CXCR6 (STRL33/Bonzo), GPR15 (BOB), GPR1, 
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CCR2, CCR3, CCR4, CCR8 and APJ.  As discussed in Chapter 2, CCR2 is thought to be 
utilized by SIVrcm in RCM, a large percentage of which lack CCR5 due to a genetic 
polymorphism.  Otherwise, however, alternative coreceptors have been considered 
largely irrelevant to infection in vivo.  For many years, alternative coreceptor use by SIV 
was considered an in vitro phenomenon, however a number of studies report SIV 
replication in T cell lines lacking CCR5, suggesting non-CCR5 entry pathways can 
mediate SIV entry (37, 61).  My work in Chapter 2 indicates that alternative entry 
pathways mediate SIVsmm transmission and replication in vivo (85). 
 
Goals of this thesis 
 
 It is well established that SIV infection of natural hosts (African NHP) results in a 
non-pathogenic infection, while HIV/SIV infection of non-natural hosts (humans and 
Asian NHP) causes pathogenic infections.  It appears that natural hosts have developed 
several mechanisms to counter the potential pathogenic effects of SIV infection such as 
attenuated chronic immune activation, “protection” of critical cell subsets required for 
maintenance of the immune system, and the ability to regulate CCR5 expression on 
specific cell subsets. 
 The goal of this thesis is to better understand the underlying mechanisms that 
contribute to the non-pathogenic nature of SIV infection in natural hosts.  Natural hosts 
exhibit significantly lower CCR5 expression on their CD4+ T cells compared to CCR5 
expression on CD4+ T cells from non-natural hosts.  However both infected natural and 
non-natural hosts exhibit robust virus replication.  This raises the question where does 
robust virus replication come from in infected natural host species since these animals 
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exhibit such low CCR5 expression on CD4+ T cells?  My work shows that in natural host 
SM, non-CCR5 entry pathways can support SIV transmission and replication in vivo.  I 
then showed that CXCR6 and GPR15 efficiently mediate SIV entry in vitro.  Based on 
these findings, we hypothesize that alternative coreceptor expression in natural hosts is 
restricted to expendable cell subsets that allow robust virus replication without causing 
disease.   
Next, we sought to study the expression profiles of CXCR6 and GPR15 on human 
and SM primary cells.  I first set out to examine the expression profile of CXCR6, 
GPR15 and CCR5 on various human cell populations since a SM-CXCR6 antibody is not 
currently available.  This work will serve as a framework for future studies comparing 
CXCR6 and GPR15 expression patterns in SM, which we hypothesize evolved to restrict 
expression to dispensable cell types. 
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Abstract 
 
In contrast to HIV infection in humans and SIV in macaques, SIV infection of natural 
hosts including sooty mangabeys (SM) is non-pathogenic despite robust virus replication.  
We identified a novel SM CCR5 allele containing a two base pair deletion (∆2) encoding 
a truncated molecule that is not expressed on the cell surface and does not support SIV 
entry in vitro.  The allele was present at a 26% frequency in a large SM colony, along 
with 3% for a CCR5∆24 deletion allele that also abrogates surface expression.  Overall, 
8% of animals were homozygous for defective CCR5 alleles and 41% were 
heterozygous.  The mutant allele was also present in wild SM in West Africa.  CD8+ and 
CD4+ T cells displayed a gradient of CCR5 expression across genotype groups, which 
was highly significant for CD8+ cells.  Remarkably, the prevalence of natural SIVsmm 
infection was not significantly different in animals lacking functional CCR5 compared to 
heterozygous and homozygous wild-type animals.  Furthermore, animals lacking 
functional CCR5 had robust plasma viral loads, which were only modestly lower than 
wild-type animals.  SIVsmm primary isolates infected both homozygous mutant and 
wild-type PBMC in a CCR5-independent manner in vitro, and Envs from both CCR5-
null and wild-type infected animals used CXCR6, GPR15 and GPR1 in addition to CCR5 
in transfected cells. These data clearly indicate that SIVsmm relies on CCR5-independent 
entry pathways in SM that are homozygous for defective CCR5 alleles and, while the 
extent of alternative coreceptor use in SM with CCR5 wild type alleles is uncertain, 
strongly suggest that SIVsmm tropism and host cell targeting in vivo is defined by the 
distribution and use of alternative entry pathways in addition to CCR5.  SIVsmm entry 
through alternative pathways in vivo raises the possibility of novel CCR5-negative target 
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cells that may be more expendable than CCR5+ cells and enable the virus to replicate 
efficiently without causing disease in the face of extremely restricted CCR5 expression 
seen in SM and several other natural host species. 
 
Author Summary 
 
SIV causes AIDS in macaques, like HIV-1 does in humans, but not in its natural host 
species such as sooty mangabeys (SM).  It is therefore important to understand infection 
in natural hosts, including the mechanisms and cellular targets of infection.  SIV 
replication in SM is thought to exclusively use CCR5 as its entry coreceptor, which 
mediates viral entry in conjunction with CD4 and is the main determinant of target cell 
tropism.  However, other molecules also function as SIV coreceptors in vitro.  We 
discovered that inactivating mutations in the CCR5 gene are common among SM and, 
furthermore, homozygous mutant animals lacking functional CCR5 still become infected 
and have high viral loads.  Ex vivo, SM lymphocytes can be infected independently of 
CCR5, and several alternative entry coreceptors are used by SIV from both CCR5+ and 
CCR5-null animals.  Thus, SIV infection in SM is mediated by other coreceptors in 
addition to CCR5, suggesting that these molecules together may determine tropism and 
cell targeting in vivo.  These results provide new insight into an important model of 
nonpathogenic natural host infection, and identify a novel role for alternative entry 
pathways suggesting a potentially broader range of target cells in vivo than currently 
recognized.  
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Introduction 
 
HIV-1 emergence into the human population resulted from cross-species 
transmission of SIVcpz from chimpanzees (Pan troglodytes), which itself resulted from 
transmission and subsequent recombination of SIVs infecting primates on which 
chimpanzees prey (4, 24).   Similarly, both simian AIDS caused by SIVmac/smm in 
rhesus macaques (RM; Macaca mulatta) and HIV-2 infection of humans originated from 
cross-species transmission of SIVsmm from naturally infected sooty mangabeys (SM; 
Cercocebus atys) (3, 31, 55).  In marked contrast to pathogenic infections leading to 
AIDS in non-natural hosts, infection in natural host species including SM is typically 
non-progressive (36, 67, 69).  Importantly, the benign nature of SM infection in vivo is 
not due to overall restricted viral replication, as both nonpathogenic natural host and 
pathogenic nonnatural host infections are characterized by robust viremia (11, 32, 59, 
68).  This observation indicates that immunodeficiency virus replication and pathogenesis 
are not inextricably linked.  Thus, understanding natural host infection has become a high 
priority for identifying key features of infection in vivo that regulate pathogenesis and, 
potentially, identify opportunities to modulate disease apart from or in addition to 
suppressing overall virus replication through pharmacologic or immune mechanisms. 
 HIV and SIV entry into target cells is initiated by binding of the viral envelope 
glycoprotein (Env) to cell surface CD4, followed by structural changes that enable 
interactions with a seven transmembrane G protein coupled cell surface receptor that then 
triggers fusion.  HIV-1 isolates use CCR5 or CXCR4 or both, and in vitro use other 
molecules infrequently.  The restricted expression of CCR5 mainly on memory CD4+ T 
cells, but broader expression of CXCR4 on both memory and naïve subsets, is thought in 
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part to underlie the accelerated disease progression seen in individuals in whom CXCR4-
using HIV-1 variants emerge late in the course of infection (6, 38, 65, 72).  In contrast, 
SIV strains use CCR5 almost universally and very rarely use CXCR4.  Sooty mangabeys 
express very low levels of CCR5 on their CD4+ T cells, a mechanism by which 
replication might be regulated in vivo and restrict transmission and pathogenesis (52, 53).  
However, most strains of SIV use a number of other alternative coreceptors in in vitro 
assays, such as CXCR6 (STRL33), the orphan receptors GPR1 and GPR15, and several 
others (18, 21, 61).  Despite the efficient use of such alternative entry pathways by 
SIVmac and SIVsmm isolates in transfected cells, infection and cell targeting in vivo is 
generally thought to be dependent on CCR5 (57).  Notably, however, the proportion of 
CD4+ T cells depleted and/or infected at a given time in macaques and mangabeys may 
exceed the proportion of cells with detectable CCR5 expression, raising the possibility 
that other pathways in addition to CCR5 might be utilized (28, 45). 
Although both natural and non-natural host infections result in high level virus 
replication, several distinguishing features provide probable clues as to possible causes 
for the distinct outcomes.  It is long believed that in addition to CD4+ T cell destruction, 
pathogenesis involves an inability to effectively replenish these populations (29, 46).  In 
pathogenic rhesus macaque infection, damage to the CD4+ T central memory (Tcm) 
subpopulation appears to play a central role in the inability of infected animals to 
replenish CD4+ T effector and effector memory (Tem) cells depleted by infection (48).  
It has been recently found that cell-associated viral loads in CD4+ Tcm are considerably 
lower in SM than RM, despite equivalent or higher Tem infection levels, which might 
enable better immune cell homeostasis in infected SM (50).  Another difference is the 
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presence of chronic generalized immune activation in infected humans and RM, whereas 
natural hosts display generalized immune activation during acute infection that then 
rapidly resolves (7, 35, 44, 68).  Chronic generalized immune activation may contribute 
to accelerated T cell turnover and ultimate depletion, and is believed to result in large part 
from translocation of gut microbial products due to gastrointestinal barrier damage during 
acute infection (9).  However, vigorous virus replication and extensive CD4+ T cell 
depletion in gut mucosal tissue occur in both natural and non-natural hosts (10, 28, 54, 
73).  A potentially important difference is Th17 CD4+ T cells, which play a critical role 
in defense against bacteria at mucosal sites, and are lost in HIV-1 and SIVmac rhesus 
macaque infection but spared in infected natural hosts (8, 12, 22, 58).  Thus, the factors 
regulating CD4+ T cell subset targeting in vivo may be central to defining the outcome of 
infection in natural or non-natural hosts.   
Interestingly, evolution appears to have favored mutations in the CCR5 gene that 
abrogate surface expression of this molecule.  An allele containing a 32 base pair 
frameshift deletion in human CCR5 that abrogates cell surface expression (CCR5∆32) is 
present at a frequency of 10% in the Caucasian population, resulting in about 18% 
heterozygous and 1% homozygous individuals.  CD4+ cells from individuals 
homozygous for CCR5∆32 are resistant to infection by CCR5-using HIV-1 isolates in 
vitro but permissive for strains that can use CXCR4, and the essential role for CCR5 in 
HIV-1 transmission and infection is demonstrated by the finding that individuals 
homozygous for CCR5∆32 are highly resistant to infection (43, 63).  Furthermore, 
heterozygous individuals can be infected but show lower viral loads and slower disease 
progression, in association with lower levels of CCR5 expression (17, 33).  Red-capped 
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mangabeys (RCM; Cercocebus torquatus) are the natural host of SIVrcm, and a 24 base 
pair in-frame deletion (CCR5∆24) that also abrogates surface expression is present at an 
allelic frequency of 87% (14).  As a result, ≥70% of RCM are homozygous for the 
mutation and do not express CCR5, and the one known exception to exclusive CCR5 
dependence by SIV in vivo is SIVrcm, which uses CCR2b for entry and cannot use 
CCR5.  The same CCR5∆24 mutant allele was also reported in two different populations 
of SM, which are closely related to RCM, but with a low allelic frequency of 4% and no 
animals homozygous for the allele were found  (14, 51).  
In this study, we identified a novel 2 base pair deletion and frameshift mutation in 
SM CCR5 (CCR5∆2) that results in a lack of surface expression and coreceptor function.  
The mutation is present at a 26% allele frequency in the large Yerkes National Primate 
Research Center (YNPRC) SM colony, and together with the previously-described ∆24 
allele results in 8% of animals lacking functional CCR5.  However CCR5-null SM are 
susceptible to natural and experimental SIVsmm infection and exhibit robust viral 
replication.  This is the first clear evidence for in vivo alternative coreceptor use by 
SIVsmm in its natural hosts, which provides an explanation for the efficient use of 
alternative coreceptors by the SIVsmm/mac family of viruses.  This data also suggests 
that cell targeting and tropism in sooty mangabeys is linked to expression and use of both 
CCR5 and additional alternative entry pathways, and identifies a third example of 
convergent evolution resulting in nonfunctional mutant CCR5 alleles among primate 
species. 
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Materials and Methods  
 
Ethics Statement  
 All animal experimentation was conducted following guidelines established by the 
Animal Welfare Act and the NIH for housing and care of laboratory animals and performed in 
accordance with Institutional regulations after review and approval by the Institutional Animal 
Care and Use Committees (IACUC) at the Yerkes National Primate Research Center (YNPRC) or 
the Tulane National Primate Research Center (TNPRC).  Studies were also reviewed and 
approved by the University of Pennsylvania IACUC. 
 
Animals and primary cells  
 These studies utilized blood cells from animals housed at the YNPRC or TNPRC.  
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood using standard 
density gradient separation methods.  For genomic analysis, approximately 0.8 x 106 PBMC were 
lysed in DNA lysis buffer (100 mM KCl; 0.1% NP40; 20 mM Tris pH 8.4; 0.5 mg/ml proteinase 
K; 200ul total volume) and used as a template for PCR amplification. For infection studies, 
cryopreserved PBMC were thawed under standard conditions and maintained at 106 cells/ml in 
RPMI supplemented with 10% FBS, 1% glutamine and 1% penicillin-streptomycin, stimulated 
for 3 days with 5 µg/ml of phytohemagglutinin (PHA; MP Biomedical), infected and then 
maintained in the same media in the presence of IL-2 (50 U/ml; Novartis).  Analysis of wild SM 
genotypes was carried out on purified DNA derived from fecal specimens collected in Cote 
d’Ivoire, which were previously characterized by mitochondrial DNA sequence analysis to 
represent 33 distinct individuals (64).  
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Cloning SM CCR5 genes 
 Full-length SM-CCR5 genes were amplified by PCR from SM genomic DNA using high 
fidelity DNA polymerase (Phusion; Finnzymes) and primers based on conserved 5’ and 3’ 
regions of published SM CCR5 coding sequences (forward: 5’-ATG GAC TAT CAA GTG TCA 
AGT CCA ACC-3’; reverse: 5’-TCA CAA GCC AAC AGA TAT TTC CTG CTC C-3’).  PCR 
reactions contained Phusion polymerase (1 unit) in HF buffer, primers (0.5 uM), dNTPs (0.2 mM) 
and 200 ng of purified genomic DNA as template in a 50 ul reaction volume.  Thermocycling 
conditions: initial denaturation at 98°C for 45 seconds, followed by 20 cycles of 98°C for 10 
seconds, 71°C for 30 seconds and 72°C for 90 seconds, with a final extension step of 72°C for 10 
minutes.  PCR amplicons were column purified (QIAquick PCR Purification kit; Qiagen) and 
then used in a second PCR reaction employing primers that incorporated a HindIII restriction site 
at the 5’ end of the coding region and a BamHI restriction site at the 3’ end of the CCR5 coding 
sequence (forward: 5’-GCT GCT ATA AGC TTC CAC CAT GGA CTA TCA AG-3’; reverse: 
5’-AGC GAG CGG ATC CTC ACA AGC CAA CAG ATA-3’; restriction sites underlined).  
Thermocycling conditions for the second PCR reaction were: an initial denaturation step at 98°C 
for 45 seconds, followed by 5 cycles of 98°C for 10 seconds, 71°C for 45 seconds and 72°C for 
60 seconds, followed by 15 cycles of 98°C for 10 seconds, 76°C for 45 seconds and 72°C for 60 
seconds, and final extension at 72°C for 10 minutes. CCR5 amplicons were cloned into the 
expression plasmid pcDNA3.1+ (Invitrogen) using HindIII and BamHI, and screened by 
restriction analysis followed by sequence confirmation.  Sequences of the smCCR5∆2, 
smCCR5∆24 and smCCR5 wild-type genes cloned here have been deposited in Genbank 
(accession numbers HM246694, HM246695 and HM246693, respectively)  
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CCR5 genotyping of SM  
 A two-step PCR-based genotyping assay was developed that identifies CCR5 wild-type 
and CCR5∆2 alleles based on differential primer annealing, using genomic DNA from lysates of 
SM PBMC.  Genomic DNA was subject to PCR amplification using the first round primers 
described above, to amplify the entire CCR5 coding region, in reactions that contained Platinum 
Taq polymerase (1 unit; Invitrogen), 1.5 mM MgCl2, primers (0.5 uM each), dNTPs (0.2 mM), 1-
3 ul DNA lysate and Taq buffer in 25 ul reaction volumes. Thermocycling conditions were: initial 
denaturation at 98°C for 45 second followed by 10 cycles of 94°C for 20 seconds, 68°C for 45 
seconds, 72°C for 60 seconds and final extension at 72°C for 10 minutes.  The product of this 
reaction (2.5 ul) was then used as a template for two separate second-round amplifications, each 
of which used a common downstream primer but different upstream primers specific for the wild-
type and ∆2 alleles, respectively (forward CCR5 wild-type: 5’-ATC ACT TGG GTG GTG GCT-
3’; forward CCR5∆2: 5’-ATC ACT TGG GTG GTG CGT-3’; common downstream: 5’-GGT 
GTT CAG GAG AAG GAC AAT GTT G-3’). The second round PCR reaction used the same 
conditions as the first reaction.  Products of the wild-type and ∆2 amplification reactions were 
visualized by 2% agarose gel electrophoresis and ethidium bromide staining, which demonstrated 
a 325 base pair product following amplification with wild-type or ∆2 primer pairs, or both for 
heterozygotes (Figure S1A). 
 Each animal was also screened for the CCR5∆24 deletion allele with a two-step PCR-
based assay.  Products of the first round PCR reaction described above, were subjected to nested 
amplification with inner primers (forward: 5’-GGC TAT CGT CCA TGC TGT GT-3’; reverse: 
5’-GAC CAG CCC CAA GAT GAC TA-3’) and thermocycling conditions as follows: initial 
denaturation at 94°C for 45 seconds, followed by 25 cycles of 94°C for 20 seconds, 59°C for 45 
seconds, 72°C for 60 second, and a final extension at 72°C for 10 minutes.  Products were 
visualized by 3% agarose gel electrophoresis and ethidium bromide staining, yielding a 205 base 
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pair product from the ∆24 allele, which was easily distinguishable from the 227-229 bp product 
from the wild-type and CCR5 ∆2 alleles (Figure S1B). 
 As a secondary confirmation of genotypes established by PCR screening, direct bulk 
sequencing was carried out on PCR amplified genomic DNA.  Amplification was done using the 
outer primer set as described above, except that Phusion high fidelity polymerase was used for 30 
cycles.  Products were column-purified and sequenced.  Genotypes were verified by manual 
inspection to confirm the presence of uniform sequences for homozygous animals, or detection of 
expected frameshifts resulting in overlapping sequences for heterozygous animals (Figure S1C). 
For fecal-derived samples, 0.5 ug of purified DNA (of which only a fraction reflected 
host-derived DNA) was PCR amplified for 35 cycles using first round outer primers as described 
above, and then subjected to nested amplification for 30 cycles using the inner primer set 
described above.  Products were then subjected to direct sequence analysis. 
 
Pseudotype luciferase reporter virus infections and coreceptor use analysis 
 SIVsmm Env-mediated entry was analyzed using luciferase-expressing reporter viruses 
pseudotyped with envelope glycoproteins of interest.  Pseudotype viruses were generated by co-
transfecting 293T cells with a plasmid encoding the NL4-3-based env-deleted luciferase-
expressing virus backbone (pNL-luc-E–R+) (16) along with expression plasmids encoding 
SIVsmm, SIVmac, HIV-1 or VSV-g envelope glycoproteins. Cells were transfected overnight 
using Fugene (Roche) and washed the next day to remove residual transfection reagent. 
Supernatants were collected 2 days later, clarified by centrifugation and stored at -80°C until use. 
Pseudotype viruses were quantified based on HIV-1 Gag p24 antigen ELISA (PerkinElmer) and 
virion infectivity measured on U87 cells stably expressing CD4 and CCR5.  Inocula were then 
standardized on the basis of infectivity in U87/CD4/CCR5 cells (1x106 relative light units; RLU). 
 The ability of pseudotype viruses to use different coreceptors was assayed in target 293T 
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cells expressing CD4 and the coreceptor of interest.  Target cells were prepared by co-
transfection with expression plasmids carrying CD4 and the desired co-receptor (1ug of each 
plasmid) using Fugene.  Cells were re-plated one day post-transfection at 2x104 cells/well in 96-
well plates and then infected the following day with pseudotype reporter viruses using equivalent 
inocula (1x106 RLU) by spin inoculation for 2 hours at 1200G.  Three days later cells were lysed 
(0.5% Triton X-100 in PBS) and infection quantified on the basis of luciferase production in 
target cells, determined by adding an equal volume of luciferase substrate (Promega) and 
measuring luciferase activity in RLU with a luminometer. 
 
SIV envelope clones and infectious viruses 
 SIV envelopes used in pseudotype infections were generated from plasma of SIVsmm-
infected CCR5 wild-type (FFv) and ∆2 homozygous (FNp) SM by single genome amplification 
(SGA) using methods and protocols previously described and cloned into pcDNA3.1 using Topo 
TA (Invitrogen)  (41, 60).  Infectious SIVsmm strains M923 and M951 were isolated as 
previously described (25) and stocks were prepared in primary SM PBMC.  
 
FACS analysis of wild-type and mutant CCR5 surface expression 
 293T cells were transfected with wild-type or mutant forms of CCR5 using Fugene 
according to manufacturer’s instructions.  One day later cells were detached by incubation in PBS 
containing 2 mM EDTA, washed in FACS buffer (PBS containing 1% FBS and 0.1% sodium 
azide), and stained with the CCR5 monoclonal antibody, clone 3A9-[APC] (BD Pharmingen) or 
isotype-matched control. Cells were analyzed using a FACS Caliber flow cytometer (BD 
Biosciences) and FloJo software (Tree Star, Inc.) to determine CCR5 surface expression.  
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SIV infections of primary SM PBMC 
 PHA-stimulated SM PBMC were plated in 96-well plates at 2.5 x 105 cells/well, 
incubated for 1 hour in the presence or absence of the CCR5 antagonist maraviroc (15 uM; 
Pfizer), and then infected with SIVsmm strains (M923 and M951) by spin inoculation (1200xg 
for 2 hours) followed by overnight incubation.  The next day cells were washed in PBS and 
maintained in media containing IL-2 (50 U/ml), with or without maraviroc (15 uM).  Cell 
supernatants were collected periodically for 3 weeks and replication measured by SIV Gag p27 
antigen in cell supernatant by ELISA (Advanced BioScience Laboratories). 
 
Analysis of SM virological and immunological parameters 
 Clinical data on infected and uninfected SM housed at YNPRC has been reported 
previously for surveys carried out in 2004-5 and 2006-7 and 2008-9 (70). CD3, CD4 and CCR5 
expression on PBMC were analyzed by FACS and plasma viral loads were measured by real-time 
PCR as described (68, 70).  For purposes of analysis, any undetectable viral loads were set at 75 
copies, the lower limit of detection.  In cases where animals seroconverted during the period of 
observation, data from prior to infection was included with uninfected animals, while data from 
after infection was included with infected animals. If multiple measurements were available for 
individual animals for any parameters, mean values were utilized. 
Statistical Analysis 
Virological and immunological data were compared between genotype groups using 
ANOVA or Kruskal-Wallis test followed by the Dunn’s multiple comparison test for multiple 
groups.  The two-sample proportions test and Chi-Square test were used for comparison between 
independent groups.  Statistical tests were performed using Prism 4.0 software and OpenEpi: 
Open Source Epidemiologic Statistics for Public Health, Version 2.3.  Data were considered 
significant when P-value was below 0.05. 
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Results 
 
Identification of a novel mutation in the sooty mangabey CCR5 gene 
We amplified the CCR5 coding sequence from SM genomic DNA, cloned it into 
an expression vector and analyzed several clones by sequence analysis.  Cloning from 
four independent PCR reactions amplifying smCCR5 from one animal (FVq) resulted in 
the identification of two distinct alleles in each of the PCR amplifications (Figure 2-1).  
One was a wild-type allele, similar to published smCCR5 sequences (smCCR5 wt), and 
the other was a novel allele containing a two base pair deletion at nucleotides 466 and 
467 of the coding sequence (smCCR5∆2), which corresponds to the fourth 
transmembrane domain (TM4) of the smCCR5 protein (Figure 2-1A). This deletion 
causes a frameshift that results in a predicted protein with 110 missense amino acids prior 
to termination at residue 265 (Figure 2-1B). In addition to this deletion, the smCCR5∆2 
allele contains two nucleotide substitutions compared with the wild-type allele identified. 
The first is a 436T>G substitution resulting in a L146V amino acid change, which is also 
found in several published wild-type smCCR5 sequences.  The second nucleotide 
substitution is 538C>T, but is masked in CCR5∆2 due to the frameshift.   
In addition to premature truncation of the protein, the mutation results in several 
charged amino acids predicted within TM4, as well as loss of both disulfide bonds 
(between the N-terminus and third extracellular loop (ECL), and between the first and 
second ECLs, respectively) that maintain secondary structure.  These features suggest 
that the mutant protein is unlikely to be configured in a manner to allow proper 
membrane placement and either normal signaling or SIV/HIV entry coreceptor function. 
 There are several other mutations in primate CCR5 genes, including the well-
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studied 32 base pair frameshift mutation in human CCR5 (CCR5∆32) (17, 43, 63) and a 
24 base pair deletion (CCR5∆24) that is common in RCM and also reported at low 
frequency in SM (14, 51).  Therefore, we examined the relationship between this SM 
CCR5∆2 deletion and the ∆24 RCM/SM and human ∆32 deletions (Figure 2-1A & B).  
The smCCR5∆2 deletion occurs in the same region of TM4, and overlaps the ∆24 
deletion, which is characterized by multiple G-T-G repeats.  In contrast, the human 
CCR5∆32 deletion occurs approximately 90 bases downstream of smCCR5∆2, within the 
second extracellular loop of the protein.  Interestingly, the SM and RCM ∆24 alleles also 
contain the 436T>G and 538C>T substitutions seen smCCR5∆2, which result in amino 
acids identical to those in human CCR5 at those respective sites (valine at position 146 
and serine at position 180; Figure 2-1B).  
 Because the CCR5∆24 mutation was previously reported to be present in animals 
at YNPRC (51), animals were screened for its presence by PCR and several ∆24 carriers 
were identified (Figure 2-S1).  We therefore generated a clone of the CCR5∆24 coding 
region by PCR of genomic DNA from one heterozygous animal.  Sequence analysis of 
this CCR5∆24 clone was similar to the sequence previously described (14, 51), except for 
a non-coding 1026G>T substitution. 
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Figure 2-1.  Sequence alignment of wild-type and mutant CCR5 genes.   
(A) Partial nucleotide sequence alignment and (B) predicted protein sequence alignment of the 
wild-type smCCR5 and smCCR5∆2 alleles (GenBank HM246693 and HM246694), the 
CCR5∆24 alleles previously described in sooty and red capped mangabeys (GenBank AF07473 
and AAC62474), and human wild-type CCR5 and CCR5∆32 alleles (GenBank DQ217934 and 
U66285).  Residues identical to the wild-type smCCR5 molecule are indicated by ‘.’ and gaps are 
shown as dashes.  Location of the frameshift resulting from the smCCR5∆2 deletion in TM4 is 
indicated by an inverted black triangle while the huCCR5∆32 frameshift is indicated by an 
inverted white triangle.  Transmembrane domains are indicated by shaded boxes and mis-sense 
amino acid sequences resulting from mutations are highlighted. 
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Cell surface expression of mutant smCCR5∆2 
 Previous studies have shown that proteins encoded by the mutant human 
CCR5∆32 and RCM/SM CCR5∆24 are not expressed on the cell surface (51, 63).  To 
test whether the smCCR5∆2 mutant gene gave rise to a protein expressed on the cell 
surface, we transfected 293T cells with wild-type and mutant SM CCR5 expression 
plasmids, along with human CCR5, and measured surface expression by flow cytometry.  
Staining utilized mAb 3A9, which cross-reacts with both human and SM CCR5 and, 
importantly, recognizes an epitope in the N-terminus that is upstream of the mutation and 
should be detected if the predicted protein were expressed.   
 As shown in Figure 2-2, surface expression of CCR5 was readily detected on 
cells transfected with SM or human wild-type CCR5.  In contrast, neither the ∆2 nor ∆24 
SM mutant CCR5 alleles gave rise to detectable surface expression.  We have so far been 
unable to assess intracellular expression because of high nonspecific intracellular staining 
with 3A9 and other anti-N-terminal CCR5 antibodies in all cells tested so far (data not 
shown).  From this data, we conclude that the frameshift mutation in smCCR5∆2 results 
in a truncated protein that is not expressed on the cell surface.  In addition, our 
observation that the CCR5∆24 mutant allele is not expressed at the cell surface is 
consistent with previous reports that this deletion abrogates cell surface expression even 
though it is not a frameshift (14, 51).  We also asked if the mutant protein might have a 
dominant negative effect on wild-type CCR5 expression, but found no change in CCR5 
staining if the wild-type CCR5 plasmid was co-transfected along with the ∆2 or ∆24 
alleles (Figure 2-S2).   
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Figure 2-2.  Surface expression of wild-type and mutant CCR5 variants in vitro.   
293T cells were transfected with expression plasmids encoding smCCR5 wild-type (orange), 
smCCR5∆2 (light blue), smCCR5∆24 (magenta) and huCCR5-wt (green), along with empty 
expression plasmid (dark blue).  Untransfected 293T cells (shaded red) serve as controls.  Cells 
were stained with an anti-CCR5 mAb (clone 3A9; APC-conjugated), which recognizes the N-
terminal region of both human and sooty mangabey CCR5 (right panel), or an isotype-matched 
control antibody (left panel).  
 55 
Prevalence of the smCCR5∆2 allele in the YNPRC sooty mangabey population 
Next we determined the prevalence of the smCCR5∆2 allele in SM housed at the 
Yerkes National Primate Research Center (YNPRC), which is the largest captive colony 
of SM in the world (n=202).  All animals were initially screened using a discriminatory 
PCR assay that specifically identifies the smCCR5 wild-type and ∆2 alleles (Figure 2-
S1A).  Animals were also screened for the ∆24 allele using primers that discriminate ∆24 
from ∆2 and wild-type alleles based on amplicon size (Figure 2-S1B).  Results were then 
verified by direct bulk sequencing of genomic DNA amplicons that confirmed the 
presence or absence of homozygous genotypes, or demonstrated frameshifting with 
sequence overlap in heterozygous animals (Figure 2-S1C). 
 The result from this analysis is shown in Table 2-1.  Five of six possible 
genotypes were identified: 50.5% of the SM carried two wild-type CCR5 alleles; 37.6% 
were heterozygous for wild-type and ∆2 alleles, and 4% of the SM were heterozygous for 
the wild-type and ∆24 alleles.  Notably, 6.4% of the SM were homozygous for the 
smCCR5∆2 allele, and 1.5% carried both ∆2 and ∆24 mutant alleles (Table 2-1).  Thus, 
nearly 8% of animals carry two CCR5 mutant alleles encoding defective CCR5 proteins.  
We did not identify any SM that were homozygous for the ∆24 allele.     
 In this SM population, analysis of allelic frequencies showed 26% of alleles 
carried the novel ∆2 deletion, 3% carried the ∆24 deletion, and 71% were wild-type.  Of 
note, the 3% frequency we found for the ∆24 allele is similar to the 4% allelic frequency 
described 12 years ago among SM housed at YNPRC (51).  We then used the allelic 
frequencies to calculate a predicted genotype distribution (Table 2-1 and Table 2-S1).  
There was close agreement between predicted and observed genotypes (p=ns; Chi-square 
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test), suggesting that the CCR5 alleles are in equilibrium in this population (of which 
~60% are SIV-infected), without evidence of selective pressure favoring or disfavoring 
any of the genotypes. 
 
Table 2-1.  Genotypic frequencies in Sooty Mangabeys at YNPRC 
Genotype: n Observed frequency (%)1 Predicted frequency (%)2,3 
W/W 102 50.5 50.8 
W/∆2 76 37.6 37.1 
W/∆24 8 4.0 3.9 
∆2/∆2 13 6.4 6.8 
∆2/∆24 3 1.5 1.4 
∆24/∆24 0 0 0.1 
Total 202   
 
1 Genotype distribution among all sooty mangabeys was determined by PCR and direct 
genomic sequence analysis 
2 Predicted genotype distribution was calculated by Punnett square analysis, based on 
allelic frequencies (W=0.71; ∆2=0.26; ∆24=0.03) derived from observed genotypes.  
3 Observed and predicted genotype frequencies are not significantly different (Chi-square 
test) 
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Prevalence of mutant CCR5 alleles in other captive and wild African sooty 
mangabey populations 
 The YNPRC colony is the largest population of SM in the US and the close match 
between predicted and observed CCR5 genotype distributions suggested an absence of 
selective pressure for or against any specific genotype.  However, we wished to 
determine the frequency with which these alleles and genotypes were present in other SM 
populations, so we analyzed genomic DNA obtained from 29 animals housed at the 
Tulane National Primate Research Center (TNPRC).  Of note, many of the monkeys that 
founded the TNPRC colony originally came from YNPRC in the 1980s, but have been 
housed and bred separately since then.  In this smaller population the ∆2 allele was 
present at a frequency of 19% and the ∆24 allele had a frequency of 5%.  As shown in 
Table 2-2 and Table 2-S2, the observed genotype frequencies in this population also do 
not differ from those predicted by allele frequencies. 
 We also asked whether the CCR5∆2 allele was present in SM in Africa.  For this 
analysis we amplified CCR5 genes from fecal-derived host DNA samples from 33 wild-
living animals in the Tai forest of Cote d’Ivoire (64).  Five animals carried both the 
CCR5∆2 and wild-type alleles, and in one animal only the ∆2 allele was detected.  An 
additional 2 animals carried both ∆24 and wild-type alleles, while the remaining animals 
revealed only wild-type sequences.  Because this analysis utilized fecal DNA containing 
limiting quantities of host DNA, we can only be certain that both alleles were captured if 
animals were found to be heterozygous.  Thus, while it is not possible to determine a 
precise allele frequency, these genotypes suggest a minimum allele frequency of 9% for 
CCR5∆2 and 3% for CCR5∆24 in this population.  This result indicates that the ∆2 allele 
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is also present in wild-living SM in Cote d’Ivoire, although likely at a lower frequency 
than in captive animals at YNPRC.         
 
Table 2-2.  Observed and predicted genotype frequencies in Sooty Mangabeys 
housed at the TNPRC1 
Genotype: n Observed frequency (%)2 Predicted frequency (%)3,4 
W/W 18 62.1 57.6 
W/∆25 7 24.1 28.8 
W/∆24 1 3.4 7.8 
∆2/∆2 1 3.4 3.6 
∆2/∆24 2 6.9 2.0 
∆24/∆24 0 0.0 0.3 
Total 29   
 
1  All animals except one are SIV-infected 
2 Genotype distribution among all sooty mangabeys was determined by PCR and direct 
genomic sequence analysis 
3 Predicted genotype distribution was calculated by Punnett square analysis, based on 
allelic frequencies (W=0.76; ∆2=0.19; ∆24=0.05) derived from observed genotypes.  
4 Observed and predicted genotype frequencies are not significantly different (Chi-square 
test). 
5  Includes one SIV-negative animal. 
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Expression of CCR5 on SM CD4+ and CD8+ T cells ex vivo 
Since overexpression studies in transfected cells suggested that neither this 
common smCCR5∆2 nor the less common ∆24 proteins are expressed on the cell surface, 
we examined the relationship between genotypes and CCR5 expression on primary SM 
CD4+ and CD8+ T cells.  To address this point, we analyzed CCR5 expression data that 
was available from animals housed at the YNPRC collected during periodic surveys 
between 2004 and 2009, focusing on uninfected animals, and grouped individuals 
according to their CCR5 genotypes.  Since neither ∆2 nor ∆24 CCR5 alleles express 
following transfection, the two mutations were combined for the purposes of this analysis 
into a homozygous wild-type, heterozygous, and homozygous deletion allele groups 
(Figure 2-3).  
As previously reported (52) and as shown in Figure 3, CCR5 expression is 
markedly greater on SM CD8+ T cells than CD4+ T cells.  In both populations there was 
a gradation in the percentage of cells staining positive for CCR5 that correlated with 
CCR5 genotype status.  The difference was particularly evident for CD8+ T cells, and the 
percentage of CCR5+/CD8+ T cells was 9.9%, 5.4% and 0.8% for wild-type, 
heterozygous and homozygous mutant groups, respectively (Figure 3A; p<0.0001 by 
Kruskal-Wallis test).  This finding indicates that the CCR5∆2 genotype acts as a 
determinant of CCR5 expression on CD8+ T cells.  There was also a strong linear 
relationship between wild-type gene dosage and CCR5 expression for CD8 cells 
(R2=0.99996; p=0.009 by Pearson’s 2-tailed correlation coefficient), consistent with the 
absence of a dominant negative effect by the mutant alleles in transfected cells (Figure 
S2).  A trend was also evident for CCR5 staining on CD4+ T cells among the three 
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groups (2.8%, 1.7% and 1.2% in the wild-type, heterozygous and homozygous mutant 
groups, respectively), which did not reach statistical significance (p=ns by Kruskal-
Wallis test) but is consistent with the notion that, although overall very low, CCR5 
expression on CD4+ T cells is also regulated by CCR5 genotype.   
Representative FACS plots showing CCR5 expression on CD4+ and CD8+ T 
cells from a homozygous wild-type, heterozygous and homozygous mutant animal are 
shown in Figure 2-3B.  We think the low level (~1%) of cells within the CCR5 gate for 
homozygous mutant animals likely represents background staining, rather than low levels 
of N-terminal expression given the result of transfection studies (Figure 2-2).  
Unfortunately, antibodies available that are directed at other epitopes in human CCR5 do 
not recognize SM CCR5. 
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Figure 2-3.  CCR5 surface expression on sooty mangabey CD4+ and CD8+ T cells ex vivo.   
(A) CCR5 staining on CD8+ T cells (left) and CD4+ T cells (right) of uninfected sooty 
mangabeys was carried out between 2004 and 2009, and analyzed according to genotype groups 
(mean ± SEM): CCR5 wild-type (W/W; n=38), heterozygous (W/∆; n=34) and homozygous 
mutant (∆/∆; n=7).  Because both ∆2 and ∆24 alleles are functionally null, they were combined 
for this analysis.  CCR5 expression by CD8+ T cells differs significantly between genotype 
groups (p<0.0001 by Kruskal-Wallis test), while the trend for CD4+ T cells does not reach 
statistical significance (p=ns).  (B) FACS plots showing CCR5 staining on CD4+ and CD8+ T 
cells from representative homozygous wild-type, heterozygous and homozygous mutant animals. 
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CCR5-null genotype does not protect sooty mangabeys from SIVsmm infection in 
vivo 
 In humans, the CCR5∆32 homozygous genotype provides powerful protection 
against HIV-1 infection (17, 43, 63).  Therefore, we asked if animals homozygous for 
CCR5-null alleles were infected by SIVsmm.  In order to more properly assess natural 
susceptibility, we restricted this analysis to YNPRC animals that were naturally infected 
(n=120) and those with documented SIV-negative status (n=72), and excluded animals in 
the colony known to have been experimentally infected (n=10).   
 As shown in Table 2-3, we found that among SM with the CCR5 homozygous 
wild-type genotype, 65% were naturally infected while 35% were uninfected, and 62% of 
CCR5 heterozygous animals were infected and 38% were uninfected.  Unexpectedly, 
among animals homozygous for CCR5-null alleles (n=14), 50% were naturally infected 
and 50% were seronegative.  Thus, animals lacking functional CCR5 genes are 
susceptible to natural SIVsmm infection.  The slightly lower prevalence of SIV infection 
among animals in the CCR5-null group was not statistically significant (p=ns; Chi-square 
test).  We also compared the distribution of genotypes within the SIV-negative and 
naturally-infected SIV populations (Table 2-4).  Similarly, there were no significant 
differences in genotype distribution between the SIV serostatus groups (p=ns for each 
genotype group; 2-sample proportions test), although a slightly lower proportion of 
homozygous CCR5 mutant animals was seen in the infected animals compared with SIV-
negative animals (5.8% vs. 9.7%; p=ns).  Therefore, the CCR5-null genotype does not 
prevent natural acquisition of SIVsmm infection.  Furthermore, neither heterozygosity 
nor homozygous null genotype appears to significantly influence SM susceptibility to 
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SIVsmm infection in vivo, and while we cannot absolutely rule out a small effect, any 
protection that might be afforded by CCR5-null status would be slight.  This result stands 
in marked contrast to the profound protective effect of CCR5∆32 homozygosity in 
humans. 
We also determined the genotypes of 10 animals at YNPRC that were infected 
experimentally.  Five of these animals were homozygous for the CCR5 wild-type gene, 
three were heterozygotes (all W/∆2) and two were homozygous for smCCR5∆2.  
Furthermore, all but one of the TNPRC animals studied are SIVsmm-infected, including 
a mix of both natural infections and experimental inoculation done in earlier decades.  
Among the infected animals were three homozygous CCR5-null animals, while the one 
uninfected animal was heterozygous (W/∆2). Therefore, SM naturally deficient in CCR5 
expression are susceptible to experimental as well as natural SIVsmm infection, 
confirming that non-CCR5 entry pathways can mediate SM natural host infection. 
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Table 2-3.  Prevalence of naturally-acquired SIV infection among YNPRC sooty 
mangabeys based on CCR5 genotype. 
Genotype1 SIV positive2 (n) SIV negative3 (n) % SIV infected4 
W/W 63 34 65 
W/∆ 50 31 62 
∆/∆ 7 7 50 
Total 120 72 63 
 
1 CCR5∆2 and ∆24 alleles were grouped together as defective for expression (∆) 
2 Includes animals known to be infected naturally in the wild or in captivity, and excludes 
10 animals infected experimentally 
3 Includes animals known to be SIV-negative at the time of last survey 
4 SIV prevalence does not differ significantly among the genotype groups (Chi-square 
test).  
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Table 2-4.  Genotypic distribution among YNPRC sooty mangabeys based on SIV 
infection status 
Genotype1 SIV positive SM (n=120)2,4 SIV negative SM (n=72)3,4 
W/W 0.525 0.472 
W/∆ 0.417 0.431 
∆/∆ 0.058 0.097 
 
1 CCR5∆2 and ∆24 alleles were grouped together as defective for expression (∆). 
2 Includes animals known to be infected naturally in the wild or in captivity, and excludes 
10 animals infected experimentally. 
3 Includes animals known to be SIV-negative at the time of last survey 
4 Differences in genotype distribution among animals based on SIV infection status are 
not statistically significant (2-sample proportions test). 
 
Influence of smCCR5 genotype on plasma viral loads and CD4 counts in SIVsmm-
infected SM 
 We next asked if CCR5 genotype affected plasma viral loads in infected animals.  
Based on previously collected data, the log10 viral load (mean ± SEM) was calculated for 
animals in each genotype group; for animals with multiple data points available, their 
mean viral load (log10) was used (Figure 2-4).  This analysis showed robust viral loads in 
all genotype groups, with a modest but statistically significant gradient in VL dependent 
on the presence of a wild-type CCR5 allele (p=0.005 by Kruskal-Wallis test).  Animals 
possessing two wild-type alleles exhibited the highest viral load (4.83 ± 0.10 log10), 
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heterozygotes showed an intermediate level (4.65 ± 0.10 log10), and infected animals with 
the CCR5-null genotype had the lowest VL (4.37 ± 0.15 log10). Thus, there is 
approximately 0.5 log10 difference in viral load in animals with two wild-type compared 
with two CCR5-null alleles.  The two important points here are that homozygous mutant 
animals have vigorous viral replication despite lacking functional CCR5, and 
simultaneously exhibit a small but significant difference in plasma viral load associated 
with increasing CCR5 gene dosage. 
 CD4 counts remain stable during chronic SIVsmm infection in the vast majority 
of animals, but some exceptions have been noted (2, 47), so we next asked if SIV-
infected animals exhibit differences in CD4 counts depending on their CCR5 genotype.  
However, there was no significant difference in CD4+ T cell levels among the genotype 
groups, whether assessed based on absolute counts (Figure 2-S3A; p=ns, Kruskal-
Wallis) or on the basis of CD4 percentage  (Figure 2-S3B; p=ns, ANOVA).  These 
results suggest that CD4+ T cell levels are maintained similarly in SIV-infected SM 
regardless of CCR5 genotype. 
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Figure 2-4.  SIV plasma viral load measurements in infected sooty mangabeys between 
genotype groups.   
Plasma viral load measurements (VL log10; means ± SEM) collected in surveys carried out 
between 2004 and 2009 of infected animals in the wild-type (n=60), heterozygous (n=49), and 
homozygous mutant (n=7) genotype groups.  The ∆2 and ∆24 alleles were combined for this 
analysis.  The difference in VL between homozygous wild-type and CCR5-null genotype groups 
(W/W vs. ∆/∆) is statistically significant (p<0.05; Dunn’s multiple comparison test) whereas the 
differences for the heterozygous group  (W/∆ vs. W/W; W/∆ vs. ∆/∆) does not reach statistical 
significance (p=ns; Dunn’s multiple comparison test). 
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smCCR5∆2 does not support SIV entry in vitro 
 We then asked if there was any chance that the smCCR5∆2 mutant allele, when 
expressed along with CD4, could support SIV infection in vitro.  We considered it 
unlikely but thought it was necessary to test directly given the staining patterns by CCR5 
mAb 3A9 in ∆2 homozygous primary mononuclear cells (Figure 2-3).  We also 
considered it important to test using SIVsmm from a CCR5∆2 homozygous infected 
animal, in case viral adaptation might have enabled use of an N-terminal region alone.  
Therefore, we generated pseudotype virions carrying Env glycoproteins cloned directly 
from plasma virus of an SIVsmm-infected CCR5∆2 homozygous animal (FNp), along 
with pseudotypes carrying Envs cloned from plasma of an infected wild-type animal 
(FFv).  Use of plasma virus ensured that these Envs were derived from actively 
replicating virus.  Target 293T cells were co-transfected with CD4 plus plasmids 
encoding wild-type smCCR5, smCCR5∆2, human CCR5 or an empty vector as a control, 
then infected with the primary SIVsmm pseudotypes.  Of note, pseudotype virions 
carrying the FNp 5.1 Env were considerably less infectious than the other Envs and very 
large amounts of this virus were required to achieve equivalent infectious inocula, which 
generally resulted in high levels of background for this Env. 
 As shown in Figure 2-5, wild-type smCCR5 and human CCR5 support infection 
of all SIVsmm variants to similar levels.  In contrast, the smCCR5∆2 allele does not 
support infection by any of the viruses.  Importantly, CCR5∆2 does not function as a 
coreceptor for Env variants from CCR5-null animals.  Thus, SIVsmm infections in 
CCR5-null animals are mediated through pathways independent of CCR5.   
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Figure 2-5.  Mutant smCCR5∆2 does not support SIV infection in vitro. 
293T cells were transfected with CD4 alone (yellow bars) or in combination with wild-type 
smCCR5 (blue bars), smCCR5∆2 (green bars) or wild-type human CCR5 (red bars). Target cells 
were infected with luciferase-expressing pseudotype virions carrying Env glycoproteins that were 
cloned from plasma of two SIVsmm-infected sooty mangabeys (FFv: W/W SM; FNp: ∆2/∆2 
SM).  Pseudotypes carrying the R5-tropic HIV-1 Env JRFL and virions lacking envelope 
glycoproteins served as controls.   Infection was measured by relative light units (RLU) in cell 
lysates 3 days after infection (mean ± SD). 
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Use of alternative coreceptors by SIVsmm isolates 
 The data presented here indicates that SIVsmm must be able to use entry 
pathways other than CCR5 for replication in vivo.  It is long known that many SIV strains 
use a number of alternative coreceptors in addition to CCR5 in vitro, although these 
viruses rarely use CXCR4.  We therefore tested the ability of SIVsmm envelopes to 
mediate infection through human CCR2b, CCR3, CCR8, GPR1, GPR15 (BOB), CXCR6 
and CXCR4.  This analysis employed the uncultured SIVsmm envelope glycoproteins 
cloned from plasma of the CCR5-null (FNp) and homozygous wild-type (FFv) infected 
animals.   
 As shown in Figure 2-6, all SIVsmm envelope glycoproteins tested mediated 
entry into cells expressing CD4 in conjunction with GPR15 and CXCR6, while GPR1 
was also used but less efficiently.  In contrast, none of the SIVsmm envelope 
glycoproteins could use CXCR4 as a coreceptor, nor CCR3 or CCR8 (data not shown).  
Interestingly, SIVsmm envelope glycoproteins failed to use CCR2b, an entry pathway 
employed by SIVrcm in RCM that typically lack CCR5 due to a high prevalence of the 
∆24 mutation (14).  Furthermore, the patterns of alternative coreceptor use were similar 
for envelope glycoproteins derived from CCR5-null and CCR5 wild-type animals, 
indicating that alternative coreceptor utilization is a feature shared by SIVsmm regardless 
of whether the host animal expresses CCR5.   While absolute luciferase production varied 
among experiments, GPR15 and CXCR6 typically supported levels of infection similar to 
that mediated by CCR5 (Figure 2-S4), although transfected targets likely represent 
maximum levels of potential utilization relative to primary cells that would express these 
molecules at physiological levels.
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Figure 2-6.  Alternative coreceptor utilization by SIVsmm Envs in vitro.  
293T cells were transfected with CD4 alone or in combination with (A) the alternative 
coreceptors GPR1, GPR15 and CXCR6, or (B) CXCR4, CCR2b or CCR5.  Target cells were then 
infected with luciferase-expressing pseudotype virions containing SIVsmm Envs from infected 
CCR5 wild-type (FFv: W/W SM) and CCR5-null (FNp: ∆2/∆2 SM) animals.  Envs from 
SIVmac239, HIV-1 JRFL and virions lacking Env served as controls.  Infection was assayed by 
RLU (mean ± SD) measured 3 days after infection. 
 72 
SIVsmm infects sooty mangabey CCR5-null primary PBMC in vitro and infection of 
wild-type PBMC is not blocked by the CCR5 antagonist maraviroc  
 We next investigated the role of non-CCR5 pathways in SIVsmm infection of 
primary SM cells, utilizing both the specific CCR5 antagonist maraviroc and CCR5-null 
PBMC derived from CCR5∆2 homozygous animals.  Maraviroc blocks chemokine 
signaling and HIV-1 Env entry through human and rhesus macaque CCR5 (37, 62), but 
blocking of SM CCR5 coreceptor function has not been reported.  Therefore, we first 
tested the effect of maraviroc on SIVsmm entry through smCCR5 in transfected cells.  As 
shown in Figure 2-7A, maraviroc blocked SIVsmm pseudotype infection of target cells 
expressing CD4 and smCCR5, reducing luciferase expression to the level seen with target 
cells expressing CD4 alone (data not shown), indicating complete blocking of smCCR5-
mediated entry by maraviroc.  In contrast, maraviroc did not inhibit SIVsmm entry 
mediated by GPR15 (Figure 2-7A), nor did it affect entry by VSV-G pseudotypes (data 
not shown), confirming that blocking is not a nonspecific effect. 
 Next we asked if maraviroc would affect productive infection of SM primary 
PBMC by infectious isolates of SIVsmm.  PBMC from an uninfected CCR5 wild-type 
(FAk) and a CCR5-null (FAz) animals were activated with PHA for three days, and then 
infected in the presence and absence of maraviroc with two SIVsmm primary isolates 
(M923 and M951), which were both derived from CCR5 wild-type infected animals.  
Viral replication was measured as SIV gag p27 levels in supernatants collected 
periodically post-infection (Figure 2-7B).   
 We first noted that both SIVsmm isolates were able to productively infect primary 
PBMC in vitro from the CCR5-null SM (FAz).  In these cells, there was no difference in 
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replication associated with CCR5 blocking by maraviroc, as expected given the lack of 
functional CCR5 encoded by the mutant genes.  This result indicates that SIVsmm 
infection of CCR5-null PBMC can occur independently of CCR5.  We then tested CCR5 
wild-type PBMC (FAk), and found that SIVsmm established productive infection in both 
the absence and presence of maraviroc.  Furthermore, there was no difference in the level 
of infection achieved when CCR5 was blocked, based on p27 antigen production.  This 
finding indicates that SIVsmm efficiently enters even CCR5-expressing SM primary 
PBMC through pathways independent of CCR5.   
 
CCR5 genotypes in sooty mangabeys with SIV evolution to X4 coreceptor use  
 Unlike HIV-1 in humans, CXCR4 use by SIV in SM is rare.  However, a few 
exceptions have been noted in which CXCR4 use emerged following experimental 
infection, which was associated with profound CD4+ T cell loss although not clinical 
AIDS (47).  Therefore, to ask if restricted CCR5+ target cell availability due to genetic 
absence of the coreceptor might be linked to CXCR4 emergence, we genotyped two 
infected CD4-low SM previously described in which CXCR4-using SIVsmm variants 
emerged (47).  Neither animal possessed a CCR5-null genotype: one was CCR5 
homozygous wild type and the other was heterozygous for the CCR5∆2 allele.  Thus, the 
fact that acquisition of CXCR4 use by SIVsmm can occur but is not associated with 
animals that genetically lack CCR5 is consistent with the notion that alternative pathway-
supported entry in vivo is robust and lack of CCR5 does not serve as a driving force in the 
rare cases with emergence of CXCR4 use. 
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Figure 2-7.  Effect of CCR5 blocking on SIVsmm use of CCR5 and entry into primary SM 
PBMC.   
(A) 293T cells were transfected with CD4 in combination with wild-type smCCR5 or GPR15.  
Two days post-transfection, target cells were pretreated for one hour with or without the CCR5 
antagonist, maraviroc (15uM), and then infected with pseudotype virions carrying SIVsmm Envs 
from a CCR5 wild-type animal (FFv) and a CCR5-null animal (FNp).  Three days later, infection 
was measured based on RLU (mean ± SD) in cell lysates.  (B) Growth curves from infection of 
primary SM PBMC (FAk: W/W SM; FAz: ∆2/∆2 SM).  Cells were stimulated for 3 days with 
PHA, then pretreated for one hour with or without maraviroc (15 uM), followed by infection with 
two different SIVsmm primary isolates (M923 and M951) in the continued presence or absence 
of maraviroc.  SIV Gag p27 antigen levels in viral supernatants were measured by ELISA. 
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Discussion  
 
We unexpectedly found that 8% of sooty mangabeys in a large US captive 
population lack functional CCR5 due to the high prevalence (29%) of mutations in the 
CCR5 gene that abrogate cell surface expression and SIV coreceptor function.  Despite 
their CCR5-null status, homozygous mutant animals are susceptible to natural as well as 
experimental SIVsmm infection and display viral loads only modestly lower than CCR5 
wild-type animals.  In vitro, SIVsmm enters primary SM lymphocytes independently of 
CCR5, and Envs from both wild type and CCR5-null infected animals use several 
alternative coreceptors in addition to CCR5, but do not use CXCR4.  These data indicate 
that both CCR5 and alternative coreceptor pathways mediate cell entry and robust viral 
replication in vivo.  The recognition that both CCR5-dependent and independent 
pathways are used in the SM natural host has significant implications for understanding 
viral tropism in vivo and CD4+ T cell subset targeting that may regulate the outcome of 
natural host infection, and raises important questions about entry coreceptor use in 
pathogenic non-human primate models of AIDS.  This finding also explains the 
previously obscure reason for widespread and efficient use of alternative coreceptors 
among the SIVmac/smm family of viruses.  Finally, it provides a third example of 
convergent evolution resulting in disruption of CCR5 function among primates, with 
consequences for virus-host interactions in SM that differ from both humans homozygous 
for CCR5∆32 and red capped mangabeys homozygous for CCR5∆24.  
From the original descriptions of alternative coreceptor use by SIVmac/smm 
viruses, and subsequently by other SIV strains, the reason for conserved use of these 
pathways has remained elusive (1, 18, 21).  It has been repeatedly shown that various SIV 
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isolates can infect primary human ∆32 homozygous PBMC independent of both CCR5 
and CXCR4, indicating that alternative coreceptors are expressed in a manner that 
supports infection in primary lymphocytes ex vivo, at least in cells of human origin (13, 
15, 23, 39, 49, 76).  Our data show for the first time that the alternative coreceptors are 
used by SIVsmm in primary simian T cells ex vivo and, more importantly, in vivo in the 
natural host from which the SIVmac/smm family derived.  Several important questions 
are raised by this finding: (1) are alternative pathways also operative in SM with wild-
type CCR5 expression, or are they only relevant if CCR5 is absent;  (2) what essential 
role or selective advantage do they provide SIVsmm in SM infection in vivo that has led 
to conservation of alternative coreceptor entry pathway use; (3) does alternative 
coreceptor use define a novel population of CCR5-negative target cells that contributes to 
the ability of host and virus to coexist without disease, and; (4) what role do alternative 
pathways play in infection of macaques, the nonhuman primate model used to study 
AIDS. 
Prior to this confirmation that alternative pathways are used in vivo, it seemed 
plausible that alternative coreceptor use by SIVsmm/mac was an in vitro epiphenomenon 
of little biological significance.  Recognizing that they are operative in vivo, it seems 
more likely that conservation of their use among SIV isolates reflects some role that, if 
not completely essential, offers a selective advantage for the virus.  Comparison of viral 
load data among the genotype groups showed robust replication in the absence of CCR5, 
but a step-wise increase associated with the presence of one or two functional CCR5 
alleles, and ex vivo blocking studies with maraviroc confirmed that both wild-type and 
CCR5-null primary PBMC possess efficient CCR5-independent entry pathways.  On one 
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hand, if the relevant coreceptor(s) are expressed only on cells that also express CCR5, the 
use of multiple pathways in vivo might be an example of functional redundancy acquired 
by SIV, reminiscent in part of the functional redundancy of the chemokine/chemokine 
receptor system.  On the other hand, if CCR5 and alternative pathways are expressed on 
distinct or only partially overlapping CD4+ T cell subsets, the 0.5 log10 VL difference 
between ∆/∆ and W/W animals may also be consistent with separate components of 
plasma viremia supported by CCR5 and non-CCR5 pathways (and an intermediate gene-
dosage effect in the presence of one CCR5 allele).  It is notable that the degree of 
depletion in SM gut CD4+ T cells exceeds the proportion that express detectable CCR5 
(28), and it will be important to determine if this is due to infection and targeting of 
CCR5-negative cells in wild-type animals mediated by other coreceptors. 
As to why alternative coreceptor use is conserved among SIVsmm and related 
strains, it seems unlikely to result from the 8% prevalence of CCR5-null animals in SM, 
and more likely reflects a unique role that provides an advantage over CCR5 alone in 
transmission, establishment of reservoirs or other aspects of infection.  Sooty mangabeys 
overall express very low levels of CCR5 on CD4+ T cells, which has been proposed as an 
evolutionary adaptive response to “protect” critical target cells and minimize 
pathogenesis (52, 53).  If so, acquisition of alternative coreceptor use by the virus may 
have reflected a “counter-measure” to maximize replication capacity, although doing so 
in a manner that still retains the nonpathogenic nature of infection.  Thus, the use of 
alternative entry pathways in vivo might enable infection of a novel CCR5-negative target 
cell population that is more expendable than CCR5+ cells, allowing the virus to replicate 
efficiently without causing disease in the face of extremely restricted CCR5 expression.  
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It will therefore be important to define the distribution of cells infected in animals with 
and without functional CCR5. 
An important question raised by these SM findings is whether alternative 
coreceptors are utilized in pathogenic infection of macaques, which is widely used to 
model human AIDS.  While CCR5 clearly plays a principal role as evidenced by 
substantial albeit variable viral suppression by CCR5 antagonists (74, 75), levels of 
CD4+ T cell infection in rhesus macaques can also substantially exceed the proportion of 
cells that express detectable CCR5 (45).  While it is possible that infection of apparently 
CCR5-negative targets reflects entry mediated by CCR5 at levels below the threshold 
detectable by FACS, our findings revive the question of whether it may be mediated by 
additional entry pathways.  Few studies have attempted to address alternative coreceptor 
use in vivo.  One report showed that mutations that abrogated GPR15 use by SIVmac had 
little effect on replication or pathogenesis in rhesus macaques (57).  Similarly, when 
pigtail macaques (Macaca nemestrina) were infected with SIVmne (also derived from 
SIVsmm), serial isolates exhibited decreasing ability to use alternative entry pathways 
when assayed in vitro (23).  On the other hand, in cynomolgus macaques (Macaca 
fascicularis) infected with SIVsmm, animals with progressive disease showed retention 
or broadening of alternative coreceptor use while those without disease progression 
showed narrowing of alternative coreceptor use (39).  Thus, it remains to be determined 
whether alternative pathways support entry in particular subsets of CD4+ T cells in the 
macaque model in vivo.  Of note, emergence of CXCR4 use is common in HIV-1 
infection of humans but exceedingly infrequent in macaques infected with SIVmac.  
HIV-1 rarely uses alternative coreceptors efficiently and evolution to CXCR4 use by 
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HIV-1 is believed to result, in part, from loss of CCR5+ target cells in late stage disease.  
Thus, the availability of efficient alternative entry pathways may be one reason that SIV 
rarely evolves to use CXCR4. 
The SIVsmm Envs examined here use GPR15 and CXCR6 for entry quite 
efficiently in vitro, and use GPR1 somewhat less efficiently. This result is concordant 
with coreceptor use patterns of multiple other SIV isolates [22,23,30].  In human blood 
cells, CXCR6 is highly expressed on CD4+ and CD8+ memory but not naïve T cells, and 
on gamma-delta T and to a lesser extent NK cells (71), although others have reported 
expression by CD4+ naïve T cells as well (66).  Interestingly, CXCR6 expression is 
regulated by T cell activation in a pattern that is tightly linked with CCR5 expression in 
response to some stimuli, but markedly different in response to others (71).  GPR15 is 
also expressed on lymphoid and myeloid cells but with less information about specific 
distribution patterns (18, 19, 21).  Of note, both CXCR6 and GPR15 are also highly 
expressed in intestinal tissues (18, 42), raising the question of whether alternative 
coreceptor use may be involved in mucosal events that play a central role in infection.  
Thus, CXCR6 and GPR15 are particularly likely candidates for mediating SM infection 
independent of CCR5, and further studies are required to determine which one or ones 
are responsible for entry into primary SM PBMC ex vivo and infection in vivo.   
One of the most important priorities in HIV/AIDS research at present is 
understanding why infected natural hosts remain healthy while rhesus macaques infected 
with SIV, humans infected with HIV-1 or HIV-2, and chimpanzees infected with SIVcpz 
develop AIDS.  Many features are shared by non-pathogenic natural host and pathogenic 
non-natural host infection including sustained high level viremia, vigorous immune 
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activation during acute infection, and extensive depletion of gut mucosal CD4+ T cells.  
In pathogenic infections it is believed that in addition to infection and loss of short-lived 
T effector and T effector memory cells, damage to long-lived CD4+ Tcm populations that 
impairs the capacity to maintain immune cell homeostasis is a critical factor in 
progressive immunodeficiency (29, 48, 56).  CCR5 levels are profoundly lower on SM 
CD4+ T cells compared with RM and humans, which may restrict the target cells 
available for infection in vivo (52, 53).  More recently it has been found that CD4+ Tcm 
in SM have particularly impaired CCR5 expression upon activation, and this corresponds 
with markedly lower levels of cell-associated infection in Tcm compared with Tem cells 
in SM, whereas both populations are similarly infected in RM (50).  Thus, in addition to 
the role of CCR5, it will be important to define the distribution and use of other 
coreceptors by SIVsmm in its natural host as well as in pathogenic rhesus macaque 
infection.  Another prominent difference between pathogenic infection and 
nonpathogenic natural host infection is the presence of sustained high level generalized 
immune activation in rhesus and humans, whereas acute infection in natural hosts is 
associated with transient immune activation that rapidly resolves (7, 20, 22, 27, 40, 68).  
Sustained immune activation during chronic infection may be an additional factor driving 
T cell turnover and depletion.  A principal mechanism driving chronic immune activation 
is believed to be translocation of microbial products due to disruption of gut mucosal 
barrier integrity that occurs early in infection (9).  However, gut mucosal lymphocyte 
infection and CD4+ T cell depletion occurs in natural host as well as pathogenic host 
infection (28, 54).  One potentially critical difference is the loss in human and rhesus 
macaque infection, but preservation in natural hosts, of mucosal CD4 Th17 cells, which 
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play a critical role in gut mucosal immune defense (8, 12, 22, 58).  Why gut Th17 CD4+ 
T cells are preserved in infected natural hosts but depleted in other hosts remains to be 
determined, but the critical role of entry coreceptors in determining tropism and cell 
subset infection in vivo suggest that both CCR5 and alternative coreceptor pathways must 
be defined in order to understand the targeting versus protection of critical CD4+ cell 
subsets. 
In addition to the YNPRC and TNPRC SM colonies, we also found the ∆2 allele 
in SM in the Tai forest of Cote d’Ivoire, confirming its presence not just in captive but 
also in wild-living West African animals, albeit at a lower frequency.  Sooty mangabeys 
at YNPRC were derived from multiple sources and their history is not well documented 
(5), so it is difficult to know for sure from what geographic regions in West Africa these 
animals descended.  Of note, the ∆2 allele was not described in earlier studies that 
reported the ∆24 allele in SM from West Africa and the YNPRC colony (14, 51).  
However, CCR5 alleles in those studies were screened by PCR amplicon size, which 
could discriminate a 24 bp size difference but is unlikely to distinguish a 2 bp difference 
between the wild type and ∆2 alleles.   
The identification here of SM CCR5∆2 brings to three the number of primates 
known to have a high prevalence of defective CCR5 alleles.  Interestingly, each of the 
three examples of populations with homozygous mutant CCR5 individuals shows distinct 
patterns of host/virus interactions.  For HIV-1 in humans, which have the lowest 
prevalence of defective CCR5 genes (~1% among Caucasians), CCR5 use is a stringent 
requirement for establishment of new infections, and its absence in the host provides 
almost complete protection from infection even though late-stage variants can use 
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CXCR4 and, occasionally, other coreceptors.  In RCM, which have the highest 
prevalence of CCR5-null individuals (≥70%), SIVrcm has adapted to use CCR2b as a 
coreceptor and lost the ability to use CCR5 (14).  SIVsmm infection in SM, which have 
an intermediate prevalence of CCR5-null individuals (8% in this population), 
demonstrate an intermediate relationship, in which alternative coreceptors efficiently 
mediate both natural and experimental infection in the absence of CCR5, but CCR5 use 
by the virus is retained, perhaps because both CCR5 and alternative pathways together 
maximize replication in the majority of animals, while the non-CCR5 pathways are 
required in the CCR5-null animals.   
It is somewhat unexpected that SIVsmm does not use CCR2b, which is the route 
of entry taken by SIVrcm in the absence of CCR5.  SM and RCM are closely related and 
sometimes considered sub-species within the same species (14, 26).  The presence of the 
same CCR5∆24 allele in RCM and SM has been interpreted as indicating an origin prior 
to separation of these populations, although it is uncertain if the remarkably high 
frequency CCR5∆24 in the RCM population reflects selective pressure exerted by an 
environmental or infectious cause, or founder effect (14).  Another question raised by our 
results is whether the SM CCR5∆2 and the SM/RCM CCR5∆24 emerged independently, 
resulting in deletions in the same region due to multiple nucleotide repeats enabling 
recombination, or given the overlapping sites whether ∆2 emerged first and additional 
events led to ∆24.  Since ∆2 is not expressed, it is unlikely that further deletions would 
lead to any additional selective advantage, and two separate recombination deletion 
events in the same region of the same gene seem more probable.   
 83 
What selective pressures might have led to three independent primate CCR5 
deletion alleles is uncertain.   CCR5∆32 has been present in the human population for at 
least 3000 years (34), far longer than HIV-1, and despite considerable speculation on 
infectious or other pressures, both what factors fueled its emergence and when it occurred 
remain enigmatic (30).  In contrast, SIV has been endemic in the SM and RCM 
populations for much longer, although whether its entry predated separation of the 
populations is uncertain (26).  The CCR5 mutation is currently not essential for 
protection from SIV-induced pathogenesis, but it is plausible that each of the mutations 
result from ancestral evolutionary pressure by pathogenic SIV infection.  For SM, genetic 
abrogation of CCR5 expression may have been an additional, complementary response to 
control pathogenesis along with phenotypic CCR5 downregulation (50, 52).  If so, in both 
SM and RCM the virus then acquired mechanisms to circumvent the restriction, by 
expanding coreceptor use for SIVsmm or switching for SIVrcm, yet the hosts then 
acquired other additional mechanisms to avoid pathogenesis.  Alternatively, it may be 
that all three CCR5 mutations, human, SM and RCM, reflect evolutionary adaptation to 
some other as-yet unidentified infectious or other environmental factor acting similarly 
on all three types of primates.  Nevertheless, whatever its origin and frequency, the SM 
CCR5∆2 mutation here expands the pathways known to support infection in this 
important natural host model, the identity, distribution and utilization of which must be 
taken into account in understanding SM infection in vivo, and the similarities or 
differences from RM infection that determine outcome from infection. 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-S1.  Analysis of sooty mangabey CCR5 genotypes. 
(A) Genomic DNA was analyzed by PCR in two separate reactions that contained primers 
specific for the wild-type or ∆2 CCR5 alleles.  (B) Genomic DNA was amplified with CCR5-
specific primers that generate an amplicon of 227-229 bp for the ∆2 and wild-type alleles, or 205 
bp for the ∆24 allele.  Note that animals 1-6 in panel A do not correspond to numbers in panel B.  
(C)  Direct sequence validation of genotypes is shown in representative chromatographs of 
animals from each of the 5 genotypes identified in this analysis: W/W, W/∆2; ∆2/∆2; W/∆24 and 
∆2/∆24.  Red arrow indicates the site of ∆2 or ∆24 frameshifts and blue arrow indicates a single 
nucleotide polymorphism (T in wild-type; G in ∆2 and ∆24 alleles) that results in a coding change 
(Leu in wild-type; Val in ∆2 and ∆24 alleles). 
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Figure 2-S2.  Lack of dominant negative effect of mutant CCR5 alleles.   
293T cells were transfected with wild-type smCCR5 plasmid (1 ug) along with plasmids 
encoding CCR5∆2, CCR5∆24 or pcDNA3 (1 ug of each plasmid).  CCR5 expression was 
determined by staining with mAb 3A9 and FACS analysis. 
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Figure 2-S3.  Blood CD4+ T cell levels in infected sooty mangabeys between genotype 
groups.  
(A) CD4+ T cell counts (cells/ul; mean ± SEM; left) and (B) CD4+ T cell as a percentage of 
CD3+ cells (mean ± SEM; right) from infected animals in the wild-type (n=60), heterozygote 
(n=49) and homozygous mutant (n=7) genotype groups.  CD4+ T cells are not significantly 
different between groups (p=ns for absolute cell counts by Kruskal-Wallis test; p=ns for %CD4+ 
cells by ANOVA). 
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Figure 2-S4.  Relative use of alternative coreceptors compared with CCR5.   
Representative experiment in which CCR5 and alternative coreceptors were tested in parallel with 
a subset of SIVsmm Env pseudotype viruses. 
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Abstract 
 
Understanding the virus/host relationship in natural hosts will enable better understanding 
of pathogenic HIV infection of humans.  SIV infection of sooty mangabey (SM) natural 
hosts does not cause disease, despite robust virus replication.  SIV uses CCR5 for entry 
into target cells, but SM and other natural hosts express very low CCR5 levels on CD4+ 
T cells.  I have shown that SIVsmm can utilize non-CCR5 entry pathways in the SM 
natural host, in vivo.  Based on in vitro infection assays, we hypothesized that CXCR6 
and GPR15 serve as alternative SIV entry coreceptors in vivo. Ultimately, we wish to 
determine whether alternative coreceptor expression patterns in SM effects target cell 
tropism in these animals.  Here, I sought to examine the expression patterns of CXCR6 
and GPR15, in addition to CCR5 on primary human cells using multi-color flow 
cytometry.  I show that on human CD4 T cells, CXCR6 and GPR15 are: i) predominantly 
expressed on memory cell subsets, ii) detected to some extent on effector cells, and iii) 
present at extremely low levels on naïve cells.  On lymphocytes, the percentage of cells 
expressing CCR5 and CXCR6 increased upon CD3/CD28-stimuation, whereas the 
percentage of GPR15-expressing cells did not change.  A large percentage of resting and 
stimulated CD4+ memory cells expressed CCR5 alone, while a similar percentage of 
CD4+ memory cells co-expressed CCR5 and CXCR6 upon stimulation.  Notably, co-
expression of CXCR6 and GPR15 was extremely rare.  This work serves as a framework 
for future studies comparing cell subset specific expression patterns in SM and non-
natural hosts.   
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Introduction 
 
 Several chemokine receptors and chemokine receptor-like orphan receptors serve 
as entry coreceptors, along with CD4, for HIV/SIV.  In vivo, CCR5 and CXCR4 are the 
primary entry coreceptors used by HIV while CCR5 was long thought to serve as the 
main coreceptor for SIV (1-4, 6, 7, 16).  Numerous studies report that SIV has a broad 
coreceptor range in vitro, and has been shown to utilize CXCR6 (Bonzo/STRL33), 
GPR15 (BOB), GPR1, ChemR23 and APJ for entry (8, 9, 19-21, 25).  However, SIV use 
of alternative coreceptors was considered an in vitro phenomenon, with the notion that 
CCR5 served as the exclusive entry coreceptor, in vivo.  My identification of SIVsmm-
infected CCR5-null SM indicated otherwise.  This observation indicates that SIVsmm 
can utilize alternative coreceptors for transmission and replication in CCR5-null SM, in 
vivo (22), and that the expression and distribution of alternative coreceptors may define 
novel cell subsets that are more expendable allowing for high virus replication without 
causing disease.   
This finding raises many questions: i) which alternative coreceptors mediate SIV 
entry in vivo, ii) what primary cell subsets express alternative coreceptors, iii) is 
alternative coreceptor use by SIV seen in other natural host species besides SM, and iv) 
does alternative coreceptor expression differ between natural hosts, that have presumably 
evolved to avoid pathogenesis, and non-natural hosts, which have not?  Based on in vitro 
entry assays by myself and others, I hypothesize that CXCR6 and GPR15 are likely entry 
coreceptors used by SIVsmm (8, 22).  Many of these studies used human-derived 
alternative coreceptors, however, a recent study from our lab confirmed that SM-derived 
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CXCR6 and GPR15 support efficient SIV entry in a transfection-based assay system 
suggesting that these alternative coreceptors may support SIVsmm entry in vivo (10).  
Since a SM-specific anti-CXCR6 antibody is not available, we set out to first 
define CXCR6 and GPR15 expression profiles on human primary cells.  CXCR6 is the 
receptor for CXCL16 (17), while GPR15 is an orphan receptor for which the natural 
ligand is not yet known (13).  Although, the expression profile of CXCR6 on human 
primary cells has been reported, the findings are conflicting.  One group reported that 
CXCR6 expression is mainly detected on naïve CD4+ T cells as well as natural killer 
(NK) cells and B lymphocytes (25), while another group reported CXCR6 expression is 
restricted to memory subsets of CD4+ and CD8+ T cells (26).  We attempted to clarify 
CXCR6 expression profiles on resting and stimulated human PBMC subsets.  The other 
coreceptor of interest is GPR15; although not much expression data is available, GPR15 
mRNA has been detected in human alveolar macrophages and CD4 lymphocytes as well 
as in activated RM PBMC (5, 11).  Additionally, a recent study revealed low level 
GPR15 expression on resting and stimulated human PBMC (14).   
The current study will allow us to compare CXCR6 and GPR15 expression 
patterns, in addition to CCR5, on human CD4+ T cell subsets.  This work serves as a 
framework for future studies comparing CXCR6 and GPR15 expression patterns in SM, 
which we hypothesize evolved to restrict expression to dispensible cell types.  In addition 
to implications for SIV, understanding alternative coreceptor expression patterns on 
human cells is important because i) while rare, HIV alternative coreceptor use has been 
described, and ii) with CCR5 knock-out efforts, alternative coreceptor use might become 
an issue. 
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Materials and Methods 
 
Isolation and stimulation of primary human cells  
Fresh human PBMC were obtained from normal donors from the University of 
Pennsylvania Immunology core.  Human PBMC from a single donor were divided into 
two equal groups.  Ten million cells were rested overnight at 37°C, and the remaining 
cells were stimulated for three days in the presence of plate-bound CD3/CD28 antibodies.  
Three days post-antibody stimulation, recombinant IL-2 was added to cells for four 
additional days in the continued presence of CD3/CD28 antibodies. 
 
Staining procedure 
Prior to antibody stimulation, cells were stained with Live/Dead Dye according to the 
manufacturer’s instructions.  On appropriate days, PBMC were stained with antibodies 
for the following: (i) lineage markers - CD3 (APC-Cy7), CD4 (FITC), CD8 (PE-Texas 
Red) and CD14, (ii) memory markers - CD27 (PE-Cy7) and CD45RO (PE-Cy5), and (iii) 
coreceptors - CCR5 (PE), CXCR6 (APC) and GPR15 (PerCP-Cy5.5).  Cells were stained 
at 4ºC in the dark for 30 minutes. After incubation, cells were washed with 1ml FACS 
buffer (PBS + 1% FBS + 0.1% sodium azide) three times.  Cells were fixed with 0.4ml 
2% paraformaldehyde in FACS buffer.   
 
Analysis 
Approximately, 2 x 105 cells were acquired on an LSR-II, and data was analyzed using 
FloJo software.  As shown in Figure 3-1, cells were gated based on characteristic light 
scatter properties followed by the selection of live cells (Figure 3-1; A,B).  Cells were 
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then separated based on CD3 and CD14 expression (C), and CD3-positive cells were 
divided based on expression of CD4 and CD8 (D).  CD3+CD4+ cells were then divided 
into naïve and memory cell subsets based on CD45RO and CD27 co-expression (E).  
Lastly, coreceptor expression levels were measured on each CD4 T cell subset (naïve, 
CD27+ memory, CD27- memory and effector cells). 
 
Quantitative PCR – Coreceptor mRNA levels 
Primary PBMC from SM were left unstimulated or cultured in the presence of 
Concanavalin A and IL-2 for up to 5 days.  CD4+ cells were sorted from PBMC at 0 and 
120 hours post-stimulation using negative selection.  Total RNA was isolated from 
purified CD4) cells using the RNAeasy extraction kit (Qiagen) according to the 
manufacturer’s instructions.  Quantification of mRNA levels for all coreceptors tested 
was performed by RT-PCR using the SYBR-Green assay.  Levels of CCR5, CXCR6, 
GPR15, GPR1 and APJ mRNA were normalized to the expression of the housekeeping 
mRNA, GAPDH. 
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Results 
 
CXCR6 and GPR15 are detected on CD4+ and double negative (CD4-/CD8-) T 
cells; CXCR6 are detected on CD8+ T cells 
I aimed to define the expression profile of CXCR6 and GPR15 on human primary 
cells; these receptors have been shown to support SIV entry in vitro.  I first determined 
the expression levels of CXCR6 and GPR15 on various T cell populations.  For the sake 
of comparison and since CCR5 expression levels are well established on human cells, we 
also measured CCR5 expression on various T cell populations.  On resting lymphocytes, 
the average percentage of cells expressing CXCR6 was 1.3% on CD4+ and CD8+ T 
cells, and 5.5% on DN T cells.  On average, GPR15 expression was detected on 2.4% 
CD4+ T cells and 12.2% DN T cells; GPR15 expression was extremely low to 
undetectable on resting CD8+ T cells.  The average percentage of resting cells expressing 
CCR5 was 8.6% on CD4+ T cells, 22.3% on CD8+ T cells and 63.2% on DN T cells.  
Flow plots from a representative donor are shown in Figure 3-2.  In all, these data 
demonstrate that CXCR6 and GPR15 expression is detected on a small percentage of 
resting lymphocytes. 
I next examined CXCR6 and GPR15 expression on CD3/CD28-stimulated cells 
from matching donors.  On stimulated lymphocytes, the average percentage of cells 
expressing CXCR6 was 8.5% on CD4 T cells, 4.2% on CD8 T cells and 13.1% on DN T 
cells.  On average, GPR15 expression was detected on 5.1% CD4 T cells and 12.2% DN 
T cells; GPR15 expression was also extremely low on stimulated CD8 T cells.  The 
average percentage of stimulated lymphocytes expressing CCR5 was 18.8% on CD4 T 
cells, 13.3% on CD8 T cells and 33.9% on DN T cells.  These results show that 
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CD3/CD28-stimulation increased the percentage of cells expressing CXCR6 and GPR15, 
as well as CCR5 (Figure 3-2).  Percentages of CXCR6, GPR15 and CCR5 expression on 
resting and stimulated cells from both donors are listed in Table 3-1. 
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Figure 3-1.  Gating strategy for analysis of coreceptor expression levels on total CD4 T cells 
and CD4 T cell subsets.   
Representative FACS plots showing the successive gating strategy used on unstimulated (rested) 
human PBMC stained for lineage markers (CD3, CD4, CD8 and CD14), memory markers 
(CD45RO and CD27), and coreceptors of interest (CCR5, CXCR6 and GPR15).  Live cells were 
separated using a Live/Dead stain.  Gated populations (cells within pink gated region) from one 
FACS plot are the total cells shown in the subsequent FACS plot.  This gating strategy was used 
to determine coreceptor expression on total CD4 T cells (plots A – D) and CD4 T cell subsets 
(plots A – E).  The percentage of cells in a particular gated area or quadrant are located at the top 
right-hand corner of the plot. 
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Figure 3-2.  CCR5, CXCR6 and GPR15 expression levels on rested and stimulated human 
CD4, CD8 and double negative (CD4-CD8-) T cells. 
Resting (overnight incubation at 37°C) and stimulated (one week incubation: three days in the 
presence of CD3/CD28 antibodies followed by four days in the presence of IL-2) human PBMC 
were stained with lineage markers (CD3, CD4, CD8 and CD14), memory markers (CD45RO and 
CD27), and coreceptors of interest (CCR5, CXCR6 and GPR15).  The percentage of cells 
expressing each coreceptor of interest on total A) CD4, B) CD8 and C) double negative (CD4-
/CD8-) T cells is displayed in each FACS plot.  A combination of florescence minus one (FMO), 
isotype-matched antibodies and staining with secondary antibody alone served as negative 
controls (data not shown).  Representative data set from one of two donors. 
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Table 3-1. Percentage of CCR5, CXCR6 and GPR15 expression on resting and stimulated human 
PBMC cell subsets
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CXCR6 and GPR15 are predominantly expressed on CD4+ memory cell subsets; 
CXCR6 and GPR15 expression is extremely low on CD4+ naïve T cells 
 
Since cells expressing CD4 are potential targets for HIV/SIV, we wanted to 
determine the expression levels of CXCR6 and GPR15, in addition to CCR5, on CD4 T 
cell subsets.  CXCR6, GPR15 and CCR5 expression is extremely low (~1.0%) on naïve 
CD4 T cells (CD45RO-/CD27+) on both resting and CD3/CD28-stimulated cells 
(Figures 3-3 & 3-4).  Similar to CCR5 expression, CXCR6 and GPR15 were both 
detected primarily on CD45RO+/CD27+ memory cells (predominantly central memory 
cells; Tcm), CD45RO+/CD27- memory cells (primarily effector memory cells; Tem) and 
effector (CD45RO-/CD27-) cell subsets, although CXCR6 and GPR15 expression was 
relatively lower than CCR5 expression on all subsets examined.   
Both CXCR6 and CCR5 expression levels are higher on CD45RO+/CD27- 
memory cells (primarily Tem) than CD45RO+/CD27+ memory cells (predominantly 
Tcm), and expression of these coreceptors is upregulated upon CD3/CD28 antibody 
stimulation.  The percentage of CXCR6-expressing cells increased from an average of 
1.3% to 10.0% on resting versus stimulated CD45RO+/CD27+ memory cells 
(predominantly Tcm), respectively, while CCR5-expressing cells increased from an 
average of 12.9% to 24.7%, respectively.  The average percentage of CD45RO+/CD27+ 
cells expressing GPR15 modestly increased from 3.9% on resting cells to 6.5% on 
stimulated cells.  On CD45RO+/CD27- memory cells (mostly Tem), CD3/CD28-
stimulation increased CXCR6 and CCR5 expression.  On average, the percentage of 
CXCR6-expressing cells increased from 3.1% on resting cells to 35.8% on stimulated 
cells, while the average percentage of CCR5-expressing cells increased from 34% to 60% 
 107 
on resting and stimulated cells, respectively.  The average percentage of GPR15-
expressing cells increased from 5.2% on resting cells to 11.6% on stimulated cells.  
However, increased GPR15 expression upon stimulation was not observed in both donors 
examined.  One donor did not show in increase in GPR15 expression on resting versus 
stimulated CD45RO+/CD27- cells (6.3% to 5.7%, respectively), while the other donor 
did (4.3% to 17.4%, respectively).  Overall, these results suggest that CXCR6 and GPR15 
are predominantly expressed on memory cell subsets (CD45RO+/CD27+ and 
CD45RO+/CD27-) and are expressed at extremely low levels on naïve CD4 T cells.  The 
percentage of cell expressing CXCR6, GPR15 and CCR5 from various cell subsets are 
displayed in Figures 3-3 and 3-4.  In addition to CD3/CD28 antibody stimulation, cells 
were also stimulated with phytohemagglutinin (PHA), which yielded similar results in 
that most coreceptor expression was detected on memory cell subsets (Table 3-2). 
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Figure 3-3.  CCR5, CXCR6 and GPR15 expression levels on rested CD4 T cell subsets. 
Resting human PBMC were stained as previously described in Figure 3-1.  Total CD4 T cells 
were divided into naïve, memory and effector cell subsets based on combinations of CD45RO 
and CD27 co-expression (plot on far left).  Arrows point from each quadrant to corresponding 
FACS plot of coreceptor expression for that particular subsets.  For each subset, the percentage of 
cells expressing a particular coreceptor, CCR5 (left), CXCR6 (middle) and GPR15 (right), is 
displayed in the FACS plot.  Representative data set from one of two donors. 
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Figure 3-4.  CCR5, CXCR6 and GPR15 expression levels on CD3/CD28-stimulated CD4 T 
cell subsets. 
CD3/CD28-stimulated human PBMC were stained as previously described in Figure 3-1.  Total 
CD4 T cells were divided into naïve, memory and effector cell subsets based on combinations of 
CD45RO and CD27 co-expression (plot on far left).  Arrows point from each quadrant to 
corresponding FACS plot of coreceptor expression for that particular subsets.  For each subset, 
the percentage of cells expressing a particular coreceptor, CCR5 (left), CXCR6 (middle) and 
GPR15 (right), is displayed in the FACS plot.  Representative data set from one of two donors. 
 110 
 
 
 
 
Table 3-2.  Percentage of CCR5, CXCR6 and GPR15 expression on resting and stimulated (PHA 
and CD3/CD28) CD4 T cell subsets.
 111 
CXCR6/CCR5 co-expression increases dramatically upon CD3/CD28-stimulation; 
CXCR6/GPR15 co-expression is rare on resting and stimulated CD4+ T cells 
  
Although HIV use of alternative coreceptors is rare in vivo, we wanted to 
determine if CXCR6 and GPR15 are co-expressed on human cells expressing CCR5.  
Furthermore, it will be interesting to ultimately compare and contrast co-expression 
profiles of CXCR6, GPR15 and CCR5 between natural and non-natural hosts.  We 
hypothesize that alternative coreceptor expression profiles on natural host primary cells 
may reveal novel target cell subsets that lack CCR5 yet express CXCR6 and/or GPR15, 
which may support viral entry and replication, in vivo.  Here we are studying human 
cells, which have not evolved under such pressure so CXCR6 and GPR15 may be 
expressed predominantly on CCR5-expressing cells. 
 We examined the co-expression of CXCR6, GPR15 and CCR5 on CD4+ memory 
subsets (CD45RO+/CD27+ and CD45RO+/CD27-) because memory subsets expressed 
most robust levels of each coreceptor alone (and effector cells were rare).  We first 
determined the percentage of cells expressing CXCR6, GPR15 and CCR5 alone on 
resting and CD3/CD28-stimulated cells.  On resting CD45RO+/CD27- memory cells, 
roughly 30% of cells expressed CCR5 alone, ~1% cells expressed only CXCR6 and 2% 
of cells expressed GPR15 alone.  Notably, the percentage of CD3/CD28-stimulated cells 
expressing CCR5 or GPR15 were similar to expression levels seen on resting cells while 
CXCR6 expression increased to roughly 3% on stimulated CD45RO+/CD27- memory 
cells (Figure 3-5A). 
 The percentage of cells expressing at least one coreceptor substantially increased 
upon CD3/CD28-stimulation.  This increase in coreceptor expression can be appreciated 
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by a decrease in the total percentage of coreceptor-negative CD45RO+/CD27- memory 
cells (primarily effector memory cells) upon stimulation.  When examining coreceptor 
co-expression on this subset, the most dramatic effect was in cells expressing both 
CXCR6 and CCR5.  CXCR6/CCR5+ cells increased substantially upon stimulation from 
2.5% on resting cells to ~30% on stimulated cells.  Less than 5% of resting and 
stimulated CD45RO+/CD27- memory cells were positive for both GPR15 and CCR5, 
with a modest increase in co-expression of these two coreceptors on stimulated cells.  
Surprisingly, CXCR6 and GPR15 co-expression was not detected on resting 
CD45RO+/CD27- memory cells, and only ~1% of stimulated cells were positive for 
these receptors.  Additionally, on average, 5% of stimulated CD45RO+/CD27- memory 
cells express all three coreceptors, which is considerably higher than the percentage of 
triple positive resting cells (Figure 3-5A).  Thus, CD3/CD28 stimulation leads to a large 
increase in CD45RO+/CD27- (Tem) cells co-expressing CXCR6 and CCR5. 
 Examination of coreceptor expression profiles on CD45RO+/CD27+ memory 
cells, reflecting predominantly Tcm cells, revealed similar co-expression trends as seen 
on CD45RO+/CD27- memory cells (primarily Tem cells).  Approximately, 85% of 
resting CD45RO+/CD27+ memory cells lacked CXCR6, GPR15 and CCR5, while the 
largest proportion of coreceptor-expressing cells were singly positive for CCR5 and 
GPR15 (Figure 3-5B).  Stimulation led to upregulation of coreceptor expression on 
CD45RO+/CD27+ memory cells, however the overall percentage of CXCR6, GPR15 or 
CCR5-expressing CD45RO+/CD27+ memory cells was considerably lower than the 
percentage of CD45RO+/CD27- memory cells expressing these coreceptors.  As seen in 
CD45RO+/CD27- memory cells, a large proportion of stimulated CD45RO+/CD27+ 
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memory cells expressed CCR5 alone or CXCR6 in combination with CCR5.  Of note, 
CXCR6 and GPR15 co-expression was not detected on resting or stimulated 
CD45RO+/CD27+ memory cells, and less than 1% of these cells expressed all three 
coreceptors (Figure 3-5B). 
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Figure 3-5.  Co-expression of CCR5, CXCR6 and GPR15 on resting and stimulated CD4 T 
cell subsets. 
Resting (blue columns) and stimulated (CD3/CD28; red columns) human PBMC were stained 
and analyzed, gating on CD3+, CD4+ CD45RO+ cells as previously described in Figure 3-1.  Co-
expression of CCR5, CXCR6 and GPR15 on A) CD27- (primarily Tem) and B) CD27+ 
(primarily Tcm) subsets was determined using Boolean gating.  For each cell subset, the mean 
percentage of coreceptor expression for all single and multiple combinations are shown (mean + 
SEM; n=2).  
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CXCR6 and GPR15 mRNA levels are relatively higher than CCR5 mRNA levels in 
resting and stimulated SM CD4 cells 
 My work (Chapter 2) showed CCR5-independent SIVsmm infection in vivo and 
in primary SM cells ex vivo, and that human-derived CXCR6 and GPR15 support robust 
SIVsmm entry in vitro.  A follow-up study from our lab showed that SM-derived CXCR6 
and GPR15 support SIV entry in vitro (10).  We hypothesize that these alternative 
coreceptors are likely used in vivo.  Antibodies to SM-CXCR6 are not currently 
available, therefore we sought to determine the mRNA levels of these alternative 
coreceptors on SM CD4+ cells using quantitative PCR.  As shown in Figure 3-6, 
CXCR6 and GPR15 mRNA levels are relatively high compared to CCR5, GPR1 and APJ 
mRNA levels in unstimulated SM CD4+ cells.  Of note, GPR1 and APJ are additional 
alternative coreceptors that have been shown to mediate SIV entry in vitro.  Furthermore, 
a decrease in CCR5, GPR1 and APJ mRNA levels occurred in SM CD4+ cells stimulated 
with concanavalin A, while the average mRNA levels of CXCR6 and GPR15 remained 
the same.  However, there is considerable variation in CXCR6 and GPR15 mRNA levels 
between individual animals tested (Figure 3-6).  Although mRNA levels do not directly 
predict protein expression levels, these results in SM primary cells are consistent with our 
hypothesis that CXCR6 and GPR15 may act as entry coreceptors in vivo in addition to 
CCR5. 
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Figure 3-6.  Coreceptor mRNA levels in resting and stimulated sooty mangabey CD4+ cells. 
Purified SM CD4+ cells were left untreated (resting) or stimulated with concanavalin A for five 
days at 37°C.  Coreceptor-specific primers were used to amplify cDNA derived from each cell 
source to determine mRNA levels using quantitative PCR.  Plasmid DNA containing each 
coreceptor of interest was used to create a standard curve.  GAPDH was used as an internal 
control and coreceptor copy numbers were plotted relative to GAPDH mRNA levels.  (Data from 
N. Francella, unpublished) 
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Discussion 
 
Chemokine receptors other than CCR5 and CXCR4 can support SIV, and to a 
lesser extent HIV, entry in vitro.  SIV use of alternative coreceptors such as CCR2, 
CCR4, CCR8, CX3CR1, APJ, GPR1, GPR15 and CXCR6 has been described 
extensively (5, 8, 19, 23, 24), and most SIV strains can propagate in human T cell lines 
that do not express CCR5 as well as in CCR5-null (∆32 homozygous) primary human 
lymphocytes (2, 12).  Since CXCR4 use by SIV is extremely rare, these data suggest that 
non-CCR5 pathways can mediate SIV infection ex vivo.  HIV primary isolates have been 
shown to use alternative coreceptors for entry, although in most cases HIV use is far less 
robust than SIV use (25).  Much of the evidence on alternative coreceptor use came from 
in vitro infection assays, and little is known about alternative coreceptor use or 
expression patterns in vivo.   
Our lab recently published the first piece of conclusive evidence that non-CCR5 
pathways support robust SIV transmission and replication in vivo.  I identified a novel 
mutant SM-CCR5 allele (∆2), and genotyped a large cohort of SM to determine the 
prevalence of mutant SM-CCR5 alleles (∆2 and ∆24), which led to the identification of a 
group of CCR5-null animals.  Surprisingly, half of the CCR5-null SM were naturally 
infected with SIVsmm.  This observation revealed that alternative coreceptors support 
SIV transmission and replication in vivo, indicating that these receptors must be 
expressed on SM CD4+ cells.  I then showed that CXCR6 and GPR15 (of human origin) 
serve as efficient SIVsmm entry pathways in vitro (22).  A follow-up study from our lab 
showed that SM-derived CXCR6 and GPR15 supported SIV entry as efficiently as CCR5 
in a pseudotype infection assay (10).  Based on these findings, we sought to study the 
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expression profiles of CXCR6 and GPR15 on human and SM primary cells.  I first set out 
to examine the expression profile of CXCR6, GPR15 and CCR5 on various human cell 
populations since there is no anti-CXCR6 antibody currently available that cross-reacts 
with the SM molecule.  
In human primary cells, I found CXCR6 and CCR5 expression detected on CD4+, 
CD8+ and DN T cells, whereas GPR15 expression was detected on CD4+ and DN T 
cells, but not on CD8+ T cells.  Since CD4+ T cells are the target cells of HIV/SIV, we 
sought to investigate the expression patterns of CXCR6 and GPR15, with that of CCR5, 
on resting and stimulated CD4+ T cell subsets.  Functional CD4+ T cell subsets 
(naïve/memory/effectors) can be distinguished based on the expression of a number of 
surface antigens such as CD45RA, CD45RO, CD27, CD62L and CCR7.  In our study, 
specific combinations of CD45RO and CD27 expression were used to define naïve, 
memory and effector cell subsets.  Of note, CD27+ memory cells (CD45RO+) are 
comprised primarily of central memory cells while CD27- memory cells are 
predominantly made up of effector memory cells.   
Chemokine receptor expression patterns are important for determining viral 
tropism.  It is well established that CCR5 is restricted to memory and effector subsets on 
CD4+ T cells, which is consistent with depletion of CD4+ memory cells in mucosal 
tissues during acute SIV infection (18).  It is likely that memory CD4+ T cells are 
preferentially targeted by HIV because they express high CCR5 levels and exist in a 
relatively activated state.  Here we found that like CCR5, CXCR6 and GPR15 are 
predominantly expressed on memory (CD27+ and CD27-) CD4+ T cell subsets, and are 
expressed at extremely low levels on naïve CD4+ T cells.  Prior studies, reporting 
 119 
CXCR6 expression patterns were discordant; one group described CXCR6 expression on 
naïve CD4+ T cells, B cells and a subset of natural killer (NK) cells, while another group 
showed CXCR6 expression is predominantly restricted to memory CD4+ and CD8+ T 
cells (25, 26).  Our finding that CXCR6 expression is highly restricted to memory CD4+ 
T cells is consistent with the latter study.   
Meanwhile, the regulation of CXCR6 has also been examined (15, 26).  One 
study showed that the expression pattern and regulation of CXCR6 paralleled that of 
CCR5, and inversely correlated with that of CXCR4 (26).  Our results corroborate these 
findings in regard to CXCR6/CCR5 co-expression.  Like CCR5, CXCR6 expression is 
highly restricted to memory CD4+ T cells and is up-regulated upon CD3/CD28 
stimulation.  Interestingly, when examining co-expression of CXCR6, GPR15 and CCR5 
on CD27+ and CD27- memory CD4+ T cells, the percentage of cells expressing both 
CXCR6 and CCR5 increased significantly upon stimulation.  Notably, a small percentage 
of cells expressed CXCR6 alone while the majority of CXCR6+ cells were also CCR5+; 
CXCR6 and GPR15 co-expression was extremely rare. 
The CD3/CD28 antibody stimulation method (plate-bound) used in this study 
resulted in the up-regulation of CXCR6, GPR15 and CCR5.  An examination of the 
percentage of cells in each CD4 T cell subset revealed that while the percentage of 
CD27+ memory cells (mostly Tcm) increased upon stimulation (38.1% of resting cells; 
53.6% of stimulated cells), a substantial proportion of cells sustained the naïve phenotype 
(41%) after stimulation.  Although our findings show a considerable increase in CXCR6 
and CCR5 expression using the CD3/CD28 plate-bound method, it is likely that up-
regulation of coreceptor expression may have increased more dramatically if the cells 
 120 
were more uniformly stimulated, such as through the use of CD3/CD28 beads.  Notably, 
PHA-administration provided a more homogenous stimulation resulting in 7.2% naïve 
CD4 T cells compared to 41% naïve CD4 T cells after CD3/CD28 (plate-bound) 
stimulation.  However, PHA stimulation did not induce a substantial increase in 
coreceptor expression (Tables 3-1 and 3-2).  This finding indicates that coreceptor 
regulation differs under different stimulation conditions. 
Although alternative coreceptor use by HIV is rare, a recent study identified a 
transmitted/founder virus that efficiently infected cell lines over-expressing GPR15, 
FPRL and APJ (14).  Based on our GPR15 expression patterns on human primary cells, 
one could speculate that this particular HIV isolate would exhibit similar viral tropism as 
an R5-tropic virus since CCR5 and GPR15 were predominantly expressed on human 
memory CD4+ T cells.   
Nevertheless, expression profiles on primary human cells may not be indicative of 
expression on primary NHP cells, which emphasizes the importance of defining CXCR6 
and GPR15 expression profiles, relative to that of CCR5, on primary SM cells.  Using 
quantitative PCR, we detected CXCR6 and GPR15 mRNA levels in SM CD4+ cells.  
Notably, CXCR6 and GPR15 mRNA levels were relatively higher than CCR5 mRNA 
levels in these cells.  Despite this promising result, we do not know how mRNA levels 
correspond to protein expression levels.  However, detection of CXCR6 and GPR15 on 
SM CD4+ cells is consistent with our hypothesis that alternative entry pathways mediate 
SIV infection in CCR5-null SM.   
These results provide a background for further studies in NHP.  Once a SM anti-
CXCR6 antibody is available, it will be important to explore CXCR6 and GPR15 
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expression profiles on primary SM cells.  Ultimately, it would be interesting to determine 
if alternative coreceptor expression profiles differ between natural and non-natural hosts, 
which may reveal novel target cell subsets that contribute to the non-pathogenic nature of 
SIV in infected natural hosts.  
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DISCUSSION & CONCLUSIONS 
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Presently, one of the most important priorities in HIV/AIDS research is 
understanding why infected natural hosts remain healthy while SIV-infected RM, HIV-
infected humans and SIVcpz-infected chimpanzees develop AIDS.  Although enormous 
progress has been made in HIV/AIDS research over the past few decades, HIV infection 
of humans remains a significant global issue.  The use of NHP models of AIDS has 
greatly enhanced our current knowledge of HIV pathogenesis, however, a comprehensive 
understanding of the mechanisms underlying non-pathogenicity seen in SIV-infected 
natural hosts is not completely understood.   
Intriguingly, natural and non-natural hosts exhibit divergent responses to SIV 
infection.  When SM and RM are inoculated with unpassaged SIVsmm, infection results 
in high viremia in both species.  SIV-infected RM exhibited severe CD4 T cell depletion, 
persistent generalized immune activation, chronic proliferation of lymphocytes, and 
ultimately died from an AIDS-like disease, while SIV-infected SM displayed modest 
lymphocyte proliferation and remained disease-free (25). This study clearly demonstrated 
that the host dependent factors, rather than properties of the virus, play a central role in 
immunodeficiency in SIV-infected RM, and highlights the importance of fully 
investigating the underlying mechanisms responsible for non-pathogenicity in SIV-
infected natural hosts.  Many studies indicate key features of natural host SIV infection 
that are associated with lack of disease progression.  Such features include:  preferential 
sparing of critical cell subsets (i.e. central memory cells) from infection (1, 19), lack of 
chronic immune activation (3, 10, 17), maintenance of mucosal immunity (8), 
preservation of gut Th17 cells (4), and preservation of T cell homeostasis (18). 
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For this dissertation, I identified a novel, non-functional SM-CCR5 mutant allele 
(CCR5∆2), and determined the prevalence of this allele in a large SM colony.  
Remarkably, animals homozygous for mutant CCR5 alleles were susceptible to SIV 
infection in vivo, indicating that non-CCR5 pathways support SIV transmission and 
replication in these CCR5-deficient animals.  Moreover, this finding challenges the long-
standing notion that CCR5 is the exclusive coreceptor used by SIV in vivo, and raises 
many questions regarding the role alternative entry pathways play in SIV infection of 
natural hosts.   
In natural host SM, alternative coreceptor use in conjunction with restricted CCR5 
expression may redirect infection to more expendable cell types, thus contributing to the 
maintenance of immune cell homeostasis (Figure 4-1).  While SIVmac utilizes 
alternative coreceptors in vitro, CCR5 expression in RM is high and the role alternative 
entry pathways play, in vivo, is less clear (Figure 4-2).  In addition to implications for 
SIV, alternative coreceptor expression and use may play a role in HIV infection of 
humans since i) while rare, HIV alternative coreceptor use has been described, and ii) 
with CCR5 knock-out efforts, acquisition of alternative coreceptor use by HIV may 
become an issue.  
 
Regulation of cellular receptors required for HIV/SIV entry and viral susceptibility  
 
in CCR5-null hosts 
 
SIV infection of multiple African NHP species is endemic and evidence suggests 
that natural hosts have been infected with SIV since ancient times, which has likely led to 
evolutionary adaptations in both virus and host.  A potential host adaptation to SIV 
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infection is the regulation of receptors and/or coreceptors required for SIV entry in a 
manner that protects critical cells from infection.  In AGM, selective downregulation of 
CD4 was observed on primary lymphocytes transitioning from a naïve to memory 
phenotype.  Surprisingly, CD4-deficient memory cells maintained T cell functions, while 
the loss of the surface-bound CD4 molecule protected these cells from SIVagm infection 
in vivo (1).  
Many natural host species (i.e. SM, AGM, sun-tailed monkeys and mandrills) 
have developed mechanisms to differentially regulate CCR5 on specific cell subsets.  
Natural hosts express extremely low levels of CCR5 on CD4+ T cells found in the 
peripheral blood and in mucosal tissues, however CD8+ T cells from these hosts, express 
considerably higher levels of CCR5 (21).  Differential regulation of CCR5 expression is 
also exhibited on SM CD4+ central memory T cells, which express significantly lower 
levels of CCR5 than SM CD4+ effector memory T cells (19).  Currently, the mechanisms 
underlying CCR5 regulation remain unknown.  However, this observation raises the 
question, is low CCR5 expression on natural host CD4+ T cells an evolutionary 
adaptation in direct response to SIV infection?   
In contrast to intrinsic regulation of CCR5, CCR5 genetic polymorphisms that 
abrogate surface expression have been identified in different host populations.  In 
humans, a 32 base-pair deletion in ECL2 has been described.  Approximately, 1% of 
Caucasians are homozygous for CCR5∆32 mutant alleles, and these individuals are 
highly resistant to HIV infection.  Notably, investigation of CCR5∆32 homozygous 
individuals confirmed that CCR5 was the main coreceptor utilized by M-tropic strains of 
HIV-1 and that these strains were critical for person-to-person transmission (16, 24).   
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Another CCR5 mutant allele, CCR5∆24, was determined to be extremely 
common in the RCM population, where ≥70% of these animals were homozygous for the 
CCR5∆24 mutant allele (5).  Despite a high prevalence of non-functional CCR5 alleles in 
the RCM population, CCR5-null animals are not protected from SIV infection.  SIVrcm 
has adapted to use CCR2b as an entry coreceptor and lost the ability to use CCR5.  
Notably, wild-type RCM-CCR5 is functional and supports entry for HIV-1, HIV-2 and 
various strains of SIV (5).   
In SM, I recently identified a novel CCR5 polymorphism, SM-CCR5∆2, and 
determined a 26% allelic frequency for this mutant allele in a large SM colony housed at 
the Yerkes primate center (23).  I found that 8% of the SM housed at Yerkes were 
homozygous for CCR5-defective alleles including CCR5∆2 and CCR5∆24 (20), which 
had an allelic frequency of 3% in this colony.  Surprisingly, 50% of the CCR5-null SM 
were naturally infected with SIVsmm, thus the CCR5-null phenotype in SM does not 
protect against SIV infection.  In contrast to SIVrcm, SIVsmm Envs cloned from a 
CCR5-null animal efficiently used CCR5 for entry as well as various alternative 
coreceptors, but not CXCR4 or CCR2b (7, 23).  Interestingly, SIVrcm and SIVsmm have 
evolved to utilize different entry pathways in the absence of CCR5.  
Remarkably, each of the three examples of populations with CCR5-null 
individuals (SM, RCM and humans) demonstrates distinct patterns of host/virus 
interactions.  Intriguingly, CCR5-null humans (non-natural host) are protected from HIV 
infection in vivo, whereas CCR5-null SM and RCM (natural hosts) remain susceptible to 
SIV infection.  The fact that natural hosts exhibit multiple mechanisms to reduce or 
completely abrogate CCR5 expression suggests that low or restricted CCR5 levels may 
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be advantageous to these hosts, possibly due to protecting critical cell subsets and a 
reduction in the homing of CD4+ T cells to sites of inflammation.  Additionally, it will be 
interesting to explore if utilization of non-CCR5 entry pathways by SIV contribute to the 
non-pathogenic nature of SIV in natural hosts.  
 
Convergent evolution of CCR5 mutant alleles 
 
 Many polymorphisms in CCR5 have been identified and investigated (2, 14, 15), 
and while a few mutant alleles were functionally defective, only three primate CCR5 
deletion alleles have resulted in CCR5-null phenotypes to date: ∆32 in humans, ∆24 in 
RCM/SM and ∆2 in SM.  Identification of the SM-CCR5∆2 allele is the third example of 
convergent evolution resulting in disruption of CCR5 expression and function in 
primates.   
Two questions regarding these mutant alleles remain unanswered: i) when did 
they arise, and ii) what selective pressure(s) led to the retention of CCR5∆32, CCR5∆24 
and CCR5∆2 in their respective species?  It is estimated that the CCR5∆24 mutant allele 
arose in an ancestral mangabey species over 10,000 years ago, prior to the formation of 
natural barriers, which likely caused a subspecies divide forming the SM and RCM 
populations (5).  According to this estimation, the CCR5∆24 mutant allele has been 
circulating in mangabey populations substantially longer than the CCR5∆32 mutant 
allele, which is currently estimated to have entered the human population roughly 3,000 
years ago (9, 11).  Presently, it is unknown when the CCR5∆2 allele entered the SM 
population; however, an estimate of the chronology of this mutation might be gained 
from evaluating the closely related RCM.  The presence of CCR5∆2 in the RCM 
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population would suggest that, like CCR5∆24, CCR5∆2 was present roughly 10,000 
years ago in an ancestral mangabey species prior to the sub-speciation of RCM and SM.  
However, the absence of CCR5∆2 in the RCM population would suggest that the 
CCR5∆2 mutant allele arose after the RCM/SM subspecies divide. 
Currently, the selective event that led to the emergence of CCR5∆24 in the 
RCM/SM population is unknown, however the emergence of CCR5∆32 in the human 
population has been attributed to infectious pathogens.  The high frequency of the 
CCR5∆32 allele in Northern European populations has been ascribed to the bubonic 
plague (“Black Death”) pandemic in the 14th century (26), however subsequent 
predictions from a population genetic model suggest that the smallpox Variola major 
virus is a more likely candidate for selection pressure leading to CCR5∆32 emergence 
(9).  Evidence clearly indicates that CCR5∆32 is not the result of selective pressure by 
HIV since this virus recently entered the human population.  However it is plausible that 
endemic SIV infections in RCM and SM populations may have selected for the 
emergence of CCR5∆24 and/or CCR5∆2 in these hosts.    
 Another question raised by our finding is whether the SM-CCR5∆2 and the 
SM/RCM CCR5∆24 mutant alleles emerged independently resulting in deletions in the 
same region of CCR5.  Both the ∆2 and ∆24 deletions occurred in a region of TM4 where 
multiple nucleotide repeats exist, which may have enabled recombination.  However, this 
potential recombination site (-GTGGTG-) is conserved in other primate species (humans, 
chimpanzees and macaques) in which the ∆24 deletion (or any other deletion at this site) 
was not observed (5).  Extensive CCR5-genotyping of other mangabey subspecies may 
identify deletions (∆2, ∆24 or others) in this particular region of CCR5.  On one hand, if 
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other deletions were observed, it would support the notion that CCR5∆2 and CCR5∆24 
alleles arose independently in a region of CCR5 that has a high occurrence of 
recombination, likely leading to nucleotide deletions.  On the other hand, the CCR5∆2 
and CCR5∆24 mutant alleles contain two identical point mutations (436T>G and 
538C>T), which result in amino acids identical to those in human CCR5 at those 
respective sites.  If CCR5∆2 and CCR5∆24 arose from independent recombination 
events, it is peculiar that the resulting mutant alleles would contain more than one 
identical point mutation, in addition to deletions in the same region.   
  
Alternative coreceptors: SIV use and viral tropism 
 
 It appears that natural hosts have developed multiple mechanisms to counter the 
potential pathogenic effects of SIV such as attenuated chronic immune activation and 
regulation of CCR5 expression through genetic polymorphisms or selective 
downregulation on specific T cell subsets (19, 21).  SIV use of alternative coreceptors in 
vitro, has been extensively described over the past decade, however the potential 
biological role of alternative coreceptor use by SIV in vivo has not been investigated. 
Discovery of the SM-CCR5∆2 mutant allele has led to the identification of SIV-infected 
CCR5-null SM emphasizing the biological relevance of non-CCR5 entry pathways in 
these hosts.  Additionally, SM-PBMC, either genetically deficient in CCR5 or treated 
with a CCR5-specific inhibitor, supported SIV replication indicating non-CCR5 entry 
pathways are available on SM primary cells (23).  Furthermore, SM-derived alternative 
coreceptors, CXCR6 and GPR15, efficiently supported entry by SIV Envs from CCR5-
expressing and CCR5-null SM, in vitro (7).  Taken together, these findings indicate that 
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alternative coreceptors play a major role in SIVsmm infection of CCR5-null SM, and 
explain the widespread and efficient use of alternative coreceptors in vitro among the 
SIVsmm/SIVmac family of viruses. 
 While alternative entry pathways solely support SIV transmission and replication 
in CCR5-null hosts, it is unknown to what extent alternative coreceptors contribute to 
SIV infection of CCR5-expressing SM.  Remarkably, a modest yet significant difference 
in viral loads was observed (~3-fold) between CCR5-expressing and CCR5-null animals, 
with an intermediate gene dosage effect seen in the presence of one CCR5 allele.  Based 
on this finding, one could speculate that CCR5 and alternative pathways are expressed on 
distinct or partially overlapping CD4+ T cell subsets, resulting in increased viral 
replication in animals possessing both CCR5 and non-CCR5 entry pathways.  One way to 
address this question is by infecting SM-PBMC with replication-competent SIVsmm 
containing a GFP reporter gene, and subsequently staining infected cells for CD4 and 
coreceptors (CCR5, CXCR6 and GPR15).  Analysis of coreceptor expression on SIV+ 
(GFP+) CD4 T cells will inform whether or not SIV infects cells expressing alternative 
coreceptors, but not CCR5. 
The recognition that both CCR5 and non-CCR5 pathways are used by SIV in SM 
natural hosts has significant implications for understanding viral tropism in vivo.  Since 
CD4/coreceptor interactions determine viral tropism and cell targeting, the findings of 
this thesis suggest that SIV infection in SM may involve target cells defined by the  
distribution and use of alternative coreceptors CXCR6 and GPR15, in addition to CCR5.  
Restricted expression of CCR5 on critical target cells (such as CD4+ central memory T 
cells) in SM has been previously described and thought to contribute to immune cell 
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homeostasis in these natural hosts (19).  Combining the sparing of critical cell subsets 
through restricted CCR5 expression and alternative coreceptor-dependent targeting may 
allow virus replication in more expendable cells without the loss of immune cell 
homeostasis.  We hypothesize that SM natural hosts may have evolved to restrict 
expression of CXCR6 and GPR15, in addition to CCR5, to dispensable cell subsets, thus 
allowing for high viral replication without causing disease.  An understanding of the 
distribution of alternative coreceptors on primary SM cell subsets will elucidate SIVsmm 
tropism in these hosts.  Additionally, strains of SIV (SIVagm and SIVrcm) from other 
natural hosts have been shown to use CXCR6 and/or GPR15 for entry in vitro (5, 6). It 
will be interesting to explore whether entry through alternative coreceptors is a conserved 
mechanism seen in multiple natural host species.   
Another interesting question is do alternative coreceptors play a role in 
pathogenic HIV/SIV infections?  In line with the hypothesis that alternative coreceptor 
use may contribute to non-pathogenicity seen in SIV-infected natural hosts, lack of 
alternative coreceptor use in pathogenic infections could result from host and/or viral 
parameters such as: i) species-specific polymorphisms that render non-natural host 
alternative coreceptors non-functional for viral entry, ii) differences in alternative 
coreceptor expression profiles between natural and non-natural hosts, which may affect 
viral tropism, iii) evolutionary adaptations in the virus, which may prevent the use of 
alternative coreceptors, and/or iv) high CCR5 expression in non-natural hosts that renders 
use of alternative coreceptors superfluous.  Along these lines, studies indicate that the 
SIVmac virus family use CXCR6, GPR15 and a number of other alternative coreceptors 
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in vitro, however there is evidence to suggest that SIVmac does not efficiently use RM-
derived CXCR6 (22).  
 In addition to implications for SIV, alternative coreceptor expression and use may 
play a role in HIV infection of humans since therapeutic strategies aimed at knocking out 
CCR5 genes, in an effort to engineer a CCR5-null phenotype, are currently underway.  
Some concerns with this approach is that the absence of CCR5 expression may drive the 
virus to utilize other coreceptors such as CXCR4, which is associated with accelerated 
disease progression (13).   In an attempt to circumvent this issue, both CCR5 and CXCR4 
can be targeted for gene disruption, however a CCR5 and CXCR4-null immune 
environment may further drive HIV to acquire the ability to use alternative coreceptors. 
Although rare, HIV use of alternative coreceptors does occur in vivo.  Recently, an HIV 
transmitted/founder virus was identified that efficiently entered cells using GPR15, but 
had impaired CCR5 and CXCR4 use (12).  Based on my preliminary findings in chapter 
3, CXCR6 and GPR15 are predominantly expressed on human CD4+ memory cells, thus 
acquisition of alternative coreceptor use may result in infecting similar target cells as an 
R5-tropic virus.   
Taken together, these data suggest that SM natural hosts may have evolved to 
restrict expression of CXCR6 and GPR15, in addition to CCR5, to dispensable cell 
subsets, thus allowing for high viral replication without causing disease.  Future studies 
comparing CXCR6 and GPR15 expression profiles in natural and non-natural hosts will 
be of importance in determining the role of alternative coreceptors in natural hosts in 
vivo.  
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Figure 4-1.  Model of potential coreceptor expression patterns on CD4+ T cells of natural 
hosts.  Model demonstrating how restriction of CCR5 and alternative coreceptors (CXCR6 and 
GPR15) to specific cell subsets may redirect viral tropism, thus sparing critical cell subsets 
required for immune cell homeostasis, while targeting dispensable cell subsets allowing robust 
replication.  Restriction of coreceptor expression (CCR5, CXCR6 and GPR15) to specific cell 
subsets may contribute to the non-pathogenic nature of SIV infection in natural hosts.
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Figure 4-2. Model of potential coreceptor expression patterns on CD4+ T cells of non-
natural hosts.  Model demonstrating that non-natural hosts express moderate to high levels of 
coreceptors on both critical and dispensable cell subsets.  This type of expression likely promotes 
equal infection in both critical and dispensable cell subsets, ultimately leading to loss of immune 
cell homeostasis and immunodeficiency.  
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